1
|
Curtis Nickel J, Foley S, Yang B, Casanovas M, Caballero R, Diez-Rivero CM, Lorenzo-Gómez MF. Reducing Recurrent Urinary Tract Infections in Women with MV140 Impacts Personal Burden of Disease: Secondary Analyses of a Randomized Placebo-controlled Efficacy Study. EUR UROL SUPPL 2024; 63:96-103. [PMID: 38585593 PMCID: PMC10995795 DOI: 10.1016/j.euros.2024.03.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/15/2024] [Indexed: 04/09/2024] Open
Abstract
Background Recurrent urinary tract infection (rUTI) remains a major health burden for women. A randomized, double-blind, placebo-controlled trial (RCT; NCT02543827) reported that female patients with rUTI receiving a sublingual vaccine, MV140, had a reduction in rUTI and increase in UTI-free rate compared with placebo. Objective To determine the impact of MV140 on the personal burden of disease in women with rUTI using secondary endpoint data from the pivotal RCT evaluating MV140. Design setting and participants In the primary RCT, female patients with rUTI enrolled in Spain and UK (from October 2015 to April 2019) were randomized to placebo (6 mo) or MV140 (3 or 6 mo), and followed for 12 mo. Individuals analyzed in this secondary analysis included those in the placebo and 3-mo (recommended dose) groups. Intervention A polybacterial sublingual vaccine, MV140 (four inactivated whole-cell bacteria-Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, and Enterococcus faecalis), or placebo. Outcome measurements and statistical analysis Symptom severity scoring, antibiotic use, safety, and multiple aspects of quality of life (QoL; Short-Form Questionnaire [SF-36]) were assessed. Results and limitations Compared with the placebo group (n = 76), the 3-mo vaccinated group (n = 74) experienced fewer overall UTI symptoms (mean symptom score 102.2 ± 222.9 vs 194.2 ± 178.8; p = 0.0002), fewer days on antibiotics (12.4 ± 17.7 vs 28.7 ± 25.2; p = 0.0001), and improved total, general, and physical SF-36 QoL improvement (differences in means for total SF-36 score 15.7; 95% confidence interval [CI] 8.80, 22.64; p < 0.0001), with only social function QoL showing no impact (4.07; 95% CI -4.93, 13.08; p = 0.3744). Conclusions Three months of MV140 is associated with a reduction of the personal burden of UTI by reducing overall UTI symptoms and antibiotic use, improving QoL in women with rUTI. Patient summary Three months of MV140 vaccine, which has previously been shown to reduce the risk of urinary tract infection safely, is associated with a reduction in the personal burden of disease.
Collapse
Affiliation(s)
| | | | - Bob Yang
- Royal Berkshire Hospital, Reading, UK
| | | | | | | | | |
Collapse
|
2
|
Montalbán-Hernández K, Cogollo-García A, Girón de Velasco-Sada P, Caballero R, Casanovas M, Subiza JL, Conejero L. MV130 in the Prevention of Recurrent Respiratory Tract Infections: A Retrospective Real-World Study in Children and Adults. Vaccines (Basel) 2024; 12:172. [PMID: 38400155 PMCID: PMC10893268 DOI: 10.3390/vaccines12020172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2023] [Revised: 01/25/2024] [Accepted: 01/30/2024] [Indexed: 02/25/2024] Open
Abstract
Respiratory tract infections (RTIs) are among the most common and important problems in clinical medicine, making antibiotics the gold standard therapeutic option regardless of their frequent viral etiology. Their excessive and inappropriate use contributes to the rapid rise of antibiotic resistance and underscores the need for alternative strategies, especially when dealing with recurrent RTIs. Prevention is the ideal alternative, but specific vaccines targeting a wide range of respiratory pathogens are scarce. MV130 is a sublingual bacterial vaccine that induces trained immunity and provides non-specific protection against respiratory pathogens in various clinical settings according to the concept of TIbV (Trained Immunity-based Vaccine). A retrospective real-world study (RWS) was conducted to evaluate the annual incidence of RTIs and the consumption of antibiotics before and after the administration of MV130, using data sourced from the medical records of 599 patients (186 children and 413 adults) who suffered from recurrent RTIs. The median number of infectious episodes in children was significantly reduced by more than 70% from 5 episodes (interquartile range (IQR) 4.0-6.0) to 1 (IQR, 0.0-2.0) (p < 0.001) after MV130. Similarly, in adults, the median number of episodes before MV130 immunization was 5 (IQR, 4.0-6.0), which dropped by more than 80% to 1 (IQR, 0.0-1.0) during the year following MV130 immunization (p < 0.001). The median number of antibiotic courses also significantly decreased for both children and adults by over 80% (p < 0.001). This RWS showed that MV130 is an effective strategy for the prevention of respiratory infections and the reduction of associated antibiotic consumption.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Laura Conejero
- Inmunotek S.L., 28805 Madrid, Spain; (K.M.-H.); (A.C.-G.); (P.G.d.V.-S.); (R.C.); (M.C.)
| |
Collapse
|
3
|
Hajdeu-Chicarosh E, Rotaru V, Levcenko S, Serna R, Victorov IA, Guc M, Caballero R, Merino JM, Arushanov E, León M. Raman scattering and spectroscopic ellipsometry studies of Sb 2S 3 and Sb 2Se 3 bulk polycrystals. Phys Chem Chem Phys 2023; 25:31188-31193. [PMID: 37955192 DOI: 10.1039/d3cp04490d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2023]
Abstract
Antimony sulfide (Sb2S3) and antimony selenide (Sb2Se3) compounds have attracted considerable attention for applications in different optoelectronic devices due to their notable optical and electrical properties, and due to the strong anisotropy of these properties along different crystallographic directions. However, the efficient use of these promising compounds still requires significant efforts in characterization of their fundamental properties. In the present study, Raman scattering and spectroscopic ellipsometry were used to investigate the vibrational and optical properties of Sb2Se3 and Sb2S3 bulk polycrystals grown by the modified Bridgman method. The first technique proved the presence of the desired Sb2S3 and Sb2Se3 phases in the analyzed ingots and confirmed the absence of any preferential crystallographic orientation at the measured surface of the samples. Spectroscopic ellipsometry was performed using a multi-oscillator Tauc-Lorentz dispersion model, and yielded a complex dielectric function of chalcogenides over the range 1.0-4.6 eV with a three phase model (ambient, surface and bulk materials). Finally, spectral data on the refractive index, the extinction coefficient, the absorption coefficient and the reflectivity at normal incidence, R, were obtained, which serve as a reference for the optical modeling of optoelectronic devices based on polycrystalline Sb2S3 and Sb2Se3 compounds.
Collapse
Affiliation(s)
- Elena Hajdeu-Chicarosh
- Institute of Applied Physics, Moldova State University, 5 Academiei str., Chisinau, MD 2028, Republic of Moldova.
| | - Victoria Rotaru
- Catalonia Institute for Energy Research (IREC), C/Jardins de les Dones de Negre 1, Sant Adrià de Besòs, Barcelona 08930, Spain
| | - Sergiu Levcenko
- Universität Leipzig, Felix Bloch Institute for Solid State Physics, Linnéstraße 5, Leipzig D-04103, Germany
| | - Rosalia Serna
- Instituto de Óptica, IO-CSIC, C/Serrano 121, Madrid 28006, Spain
| | - Ivan A Victorov
- Belarusian State University of Informatics and Radioelectronics, P. Brovka 6, Minsk 220013, Belarus
| | - Maxim Guc
- Catalonia Institute for Energy Research (IREC), C/Jardins de les Dones de Negre 1, Sant Adrià de Besòs, Barcelona 08930, Spain
| | - Raquel Caballero
- Instituto de Óptica, IO-CSIC, C/Serrano 121, Madrid 28006, Spain
- Universidad Autónoma de Madrid, Department of Applied Physics, C/Francisco Tomás y Valiente 7, Madrid 28049, Spain
| | - José Manuel Merino
- Universidad Autónoma de Madrid, Department of Applied Physics, C/Francisco Tomás y Valiente 7, Madrid 28049, Spain
| | - Ernest Arushanov
- Institute of Applied Physics, Moldova State University, 5 Academiei str., Chisinau, MD 2028, Republic of Moldova.
- CENTERA Laboratories, Institute of High-Pressure Physics, Polish Academy of Sciences, Warsaw PL-01-142, Poland
| | - Máximo León
- Universidad Autónoma de Madrid, Department of Applied Physics, C/Francisco Tomás y Valiente 7, Madrid 28049, Spain
| |
Collapse
|
4
|
González-Santiago S, Gil-Gil M, Carrasco E, Martínez-Jáñez N, Adamo B, Antolín S, Alonso J, Vethencourt A, Martínez-Vila C, Galve E, Rojo F, Caballero R, Casas M, Cortazar E, McCulloch L, Vedovato JC, Martín M. P006 Randomized Phase II trial evaluating three anti-diarrhoeal prophylaxis strategies in patients with HER2+/HR+ early breast cancer treated with extended adjuvant neratinib (DIANER GEICAM/2018-06). Breast 2023. [DOI: 10.1016/s0960-9776(23)00125-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/18/2023] Open
|
5
|
de la Cruz-Merino L, Gion M, Cruz J, Alonso-Romero JL, Quiroga V, Moreno F, Andrés R, Santisteban M, Ramos M, Holgado E, Cortés J, López-Miranda E, Cortés A, Henao F, Palazón-Carrión N, Rodriguez LM, Ceballos I, Soto A, Puertes A, Casas M, Benito S, Chiesa M, Bezares S, Caballero R, Jiménez-Cortegana C, Sánchez-Margalet V, Rojo F. Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study. BMC Cancer 2022; 22:1258. [PMID: 36463104 PMCID: PMC9719636 DOI: 10.1186/s12885-022-10363-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Accepted: 11/24/2022] [Indexed: 12/04/2022] Open
Abstract
BACKGROUND We evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and the pyrimidine antimetabolite gemcitabine in HER2- advanced breast cancer (ABC) patients previously treated in the advanced setting, in order to explore a potential synergism that could eventually obtain long term benefit in these patients. METHODS HER2-negative ABC patients received 21-day cycles of pembrolizumab 200 mg (day 1) and gemcitabine (days 1 and 8). A run-in-phase (6 + 6 design) was planned with two dose levels (DL) of gemcitabine (1,250 mg/m2 [DL0]; 1,000 mg/m2 [DL1]) to determine the recommended phase II dose (RP2D). The primary objective was objective response rate (ORR). Tumor infiltrating lymphocytes (TILs) density and PD-L1 expression in tumors and myeloid-derived suppressor cells (MDSCs) levels in peripheral blood were analyzed. RESULTS Fourteen patients were treated with DL0, resulting in RP2D. Thirty-six patients were evaluated during the first stage of Simon's design. Recruitment was stopped as statistical assumptions were not met. The median age was 52; 21 (58%) patients had triple-negative disease, 28 (78%) visceral involvement, and 27 (75%) ≥ 2 metastatic locations. Progression disease was observed in 29 patients. ORR was 15% (95% CI, 5-32). Eight patients were treated ≥ 6 months before progression. Fourteen patients reported grade ≥ 3 treatment-related adverse events. Due to the small sample size, we did not find any clear association between immune tumor biomarkers and treatment efficacy that could identify a subgroup with higher probability of response or better survival. However, patients that experienced a clinical benefit showed decreased MDSCs levels in peripheral blood along the treatment. CONCLUSION Pembrolizumab 200 mg and gemcitabine 1,250 mg/m2 were considered as RP2D. The objective of ORR was not met; however, 22% patients were on treatment for ≥ 6 months. ABC patients that could benefit of chemoimmunotherapy strategies must be carefully selected by robust and validated biomarkers. In our heavily pretreated population, TILs, PD-L1 expression and MDSCs levels could not identify a subgroup of patients for whom the combination of gemcitabine and pembrolizumab would induce long term benefit. TRIAL REGISTRATION ClinicalTrials.gov and EudraCT (NCT03025880 and 2016-001,779-54, respectively). Registration dates: 20/01/2017 and 18/11/2016, respectively.
Collapse
Affiliation(s)
- L. de la Cruz-Merino
- grid.411375.50000 0004 1768 164XDepartment of Medical Oncology, Medicine Department, Virgen Macarena University Hospital, University of Seville, Dr. Fedriani St, No. 3, Seville, 41009 Spain ,grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
| | - M. Gion
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.411347.40000 0000 9248 5770Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - J. Cruz
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.411220.40000 0000 9826 9219Department of Medical Oncology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
| | - JL. Alonso-Romero
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.411372.20000 0001 0534 3000Department of Medical Oncology, Hospital Clínico Universitario Virgen de La Arrixaca-IMIB, Murcia, Spain
| | - V. Quiroga
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.418701.b0000 0001 2097 8389Department of Medical Oncology, Badalona Applied Research Group in Oncology (B-ARGO Group), Catalan Institute of Oncology, Badalona, Spain
| | - F. Moreno
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.411068.a0000 0001 0671 5785Department of Medical Oncology, Hospital Clínico Universitario San Carlos, Madrid, Spain
| | - R. Andrés
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.411050.10000 0004 1767 4212Department of Medical Oncology, Hospital Clínico Universitario Lozano Blesa, Saragossa, Spain
| | - M. Santisteban
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.411730.00000 0001 2191 685XDepartment of Medical Oncology, Clínica Universidad de Navarra, Navarra, Spain ,grid.508840.10000 0004 7662 6114IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - M. Ramos
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.418394.3Department of Medical Oncology, Centro Oncológico de Galicia, A Coruña, Spain
| | - E. Holgado
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.414808.10000 0004 1772 3571Department of Medical Oncology, Hospital La Luz, Quironsalud, Madrid, Spain
| | - J. Cortés
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,International Breast Cancer Center (IBCC), Quiron Group, Barcelona and Madrid, Spain ,grid.411083.f0000 0001 0675 8654Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain ,grid.119375.80000000121738416Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain
| | - E. López-Miranda
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.411347.40000 0000 9248 5770Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - A. Cortés
- grid.411347.40000 0000 9248 5770Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - F. Henao
- grid.411375.50000 0004 1768 164XDepartment of Medical Oncology, Medicine Department, Virgen Macarena University Hospital, University of Seville, Dr. Fedriani St, No. 3, Seville, 41009 Spain ,grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
| | - N. Palazón-Carrión
- grid.411375.50000 0004 1768 164XDepartment of Medical Oncology, Medicine Department, Virgen Macarena University Hospital, University of Seville, Dr. Fedriani St, No. 3, Seville, 41009 Spain ,grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
| | - L. M. Rodriguez
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.411220.40000 0000 9826 9219Department of Medical Oncology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
| | - I. Ceballos
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.411220.40000 0000 9826 9219Department of Medical Oncology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
| | - A. Soto
- grid.411372.20000 0001 0534 3000Department of Medical Oncology, Hospital Clínico Universitario Virgen de La Arrixaca-IMIB, Murcia, Spain
| | - A. Puertes
- grid.411372.20000 0001 0534 3000Department of Medical Oncology, Hospital Clínico Universitario Virgen de La Arrixaca-IMIB, Murcia, Spain
| | - M. Casas
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
| | - S. Benito
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
| | - M. Chiesa
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
| | - S. Bezares
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
| | - R. Caballero
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
| | - C. Jiménez-Cortegana
- grid.411375.50000 0004 1768 164XMedical Biochemistry and Molecular Biology and Immunology Department, Virgen Macarena University Hospital, University of Seville, Seville, Spain
| | - V. Sánchez-Margalet
- grid.411375.50000 0004 1768 164XMedical Biochemistry and Molecular Biology and Immunology Department, Virgen Macarena University Hospital, University of Seville, Seville, Spain
| | - F. Rojo
- grid.430580.aGEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain ,grid.419651.e0000 0000 9538 1950Pathology Department, IIS-Fundación Jiménez Díaz, Madrid, Spain ,CIBERONC-ISCIII, Madrid, Spain
| |
Collapse
|
6
|
Caballero R, Dago M, Camara-Checa A, Crespo-Garcia T, Rubio-Alarcon M, Rapun J, Marin M, Tamargo J, Delpon E. Empagliflozin and dapagliflozin increase Na current in human cardiomyocytes. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Empagliflozin (EMPA) and dapagliflozin (DAPA) are sodium-glucose cotransporter 2 inhibitors (SGLT2i) used for the treatment of type 2 Diabetes Mellitus (T2DM). Both drugs reduce morbidity and mortality in heart failure (HF) patients with reduced or preserved ejection fraction, even in the absence of T2DM. Moreover, these drugs decrease ventricular arrhythmias and sudden cardiac death in HF patients. The sodium current (INa), carried by Nav1.5 channels, is responsible for cardiac action potential (AP) depolarization and determines excitability and conduction velocity. In HF patients, the expression of Nav1.5 channels is reduced, leading to a decrease of ventricular excitability that enhances the arrhythmic risk.
Purpose
We aimed to determine the effects of EMPA and DAPA on human cardiac INa and AP characteristics.
Methods
Peak INa and ventricular-like APs were recorded in cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CM) using patch-clamp techniques. INa was also recorded in CHO cells transiently transfected with human Nav1.5+Navβ1 channels. In all cases, EMPA or DAPA (1 μM) were added to culture media and incubated for 24-h.
Results
APs recorded in hiPSC-CMs exhibited automatic activity and incubation with EMPA or DAPA did not modify spontaneous beating frequency (0.39±0.04 Hz; P>0.05, n≥16). In cells driven at 1 Hz, none of the drugs modified resting membrane potential (−76.7±1.4 mV; P>0.05, n≥11), but significantly increased AP amplitude from 98.6±3.6 to 105±2.2 (DAPA) and 107±2.3 mV (EMPA) (P<0.05). Interestingly, only EMPA lengthened AP duration measured at 20%, 50%, and 90% (from 605.6±31.3 to 760.5±59.0 ms, P<0.05) of repolarization. In hiPSC-CMs EMPA increased maximum INa density by 64% (from −156.0±28.0 to −256.4±28.1 pA/pF, P<0.05, n≥7) and shifted the midpoint (Vh) of the inactivation curve to more hyperpolarized potentials (from −97.3±4.5 to −108.6±4.4 mV, P<0.05, n≥7). In turn, DAPA increased maximum INa density by 24% (to −193.8±26.6 pA/pF) and shifted the Vh of the activation curve to more negative potentials (from −47.2±1.6 mV to −55.5±2.8 mV, P<0.05), an effect that would increase the INa at negative potentials coinciding with channel opening. None of the drugs modified the time course of current activation or inactivation. In CHO cells, EMPA and DAPA effects on INa were identical to those observed on hiPSC-CM. These results suggest that both SGLT2i increase INa by enhancing Nav1.5 expression into the cell membrane, by a direct gating effect on the channel, or by a combination of both.
Conclusions
In human cardiomyocytes, EMPA and DAPA increase INa and the AP amplitude. Moreover, EMPA, but not DAPA, prolonged AP duration. We propose that EMPA and DAPA exhibit a unique mechanism that increases cardiac excitability and conduction velocity and could contribute to the prevention of arrhythmic events in HF patients.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Ministerio de Ciencia e innovaciόnInstituto de de Salud Carlos III
Collapse
Affiliation(s)
- R Caballero
- Complutense University of Madrid , Madrid , Spain
| | - M Dago
- Complutense University of Madrid , Madrid , Spain
| | | | | | | | - J Rapun
- Complutense University of Madrid , Madrid , Spain
| | - M Marin
- Complutense University of Madrid , Madrid , Spain
| | - J Tamargo
- Complutense University of Madrid , Madrid , Spain
| | - E Delpon
- Complutense University of Madrid , Madrid , Spain
| |
Collapse
|
7
|
Nieto A, Mazón Á, Nieto M, Ibáñez E, Jang D, Calaforra S, Alba P, Pérez‐Francés C, Llusar R, Montoro J, de Mateo A, Alamar R, El‐Qutob D, Fernández J, Moral L, Toral T, Antón M, Andreu C, Ferrer Á, Flores I, Cerdá N, del Pozo S, Caballero R, Subiza JL, Casanovas M. First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy. Allergy 2022; 77:3096-3107. [PMID: 35570712 PMCID: PMC9796063 DOI: 10.1111/all.15374] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2022] [Revised: 03/31/2022] [Accepted: 04/20/2022] [Indexed: 01/28/2023]
Abstract
BACKGROUND Polymerized allergens conjugated to non-oxidized mannan (PM-allergoids) are novel vaccines targeting dendritic cells (DCs). Previous experimental data indicate that PM-allergoids are readily taken up by DCs and induce Treg cells. This first-in-human study was aimed to evaluate safety and to find the optimal dose of house dust mite PM-allergoid (PM-HDM) administered subcutaneously (SC) or sublingually (SL). METHODS In a randomized, double-blind, double-dummy, placebo-controlled trial, 196 subjects received placebo or PM-HDM at 500, 1000, 3000, or 5000 mannan-conjugated therapeutic units (mTU)/mL in 9-arm groups for 4 months. All subjects received 5 SC doses (0.5 ml each) every 30 days plus 0.2 ml SL daily. The primary efficacy outcome was the improvement of titrated nasal provocation tests (NPT) with D. pteronyssinus at baseline and at the end of the study. All adverse events and reactions were recorded and assessed. Secondary outcomes were the combination of symptom and medication scores (CSMS) and serological markers. RESULTS No moderate or severe adverse reactions were reported. Subjects improving the NPT after treatment ranged from 45% to 62% in active SC, 44% to 61% in active SL and 16% in placebo groups. Statistical differences between placebo and active groups were all significant above 500 mTU, being the highest with 3000 mTU SL (p = 0.004) and 5000 mTU SC (p = 0.011). CSMS improvement over placebo reached 70% (p < 0.001) in active 3000 mTU SC and 40% (p = 0.015) in 5000 mTU SL groups. CONCLUSIONS PM-HDM immunotherapy was safe and successful in achieving primary and secondary clinical outcomes in SC and SL at either 3000 or 5000 mTU/ml.
Collapse
Affiliation(s)
- Antonio Nieto
- Unit of Pediatric Allergy and PneumologyHospital Universitari i Politècnic la FeValenciaSpain
| | - Ángel Mazón
- Unit of Pediatric Allergy and PneumologyHospital Universitari i Politècnic la FeValenciaSpain
| | - María Nieto
- Unit of Pediatric Allergy and PneumologyHospital Universitari i Politècnic la FeValenciaSpain
| | - Ethel Ibáñez
- Department of AllergyHospital Universitari i Politècnic la FeValenciaSpain
| | - Dah‐Tay Jang
- Unit of Pediatric Allergy and PneumologyHospital Universitari i Politècnic la FeValenciaSpain
| | | | - Pilar Alba
- Allergy ServiceHospital ManisesValenciaSpain
| | | | - Ruth Llusar
- Allergy ServiceUniversity Hospital Doctor PesetValenciaSpain
| | - Javier Montoro
- Allergy ServiceUniversity Hospital Arnau de VilanovaValenciaSpain
| | | | | | - David El‐Qutob
- Allergy ServiceUniversity Hospital de la PlanaCastellónSpain
| | - Javier Fernández
- Allergy ServiceHospital General Universitario Dr. Balmis, ISABIALAlicanteSpain
| | - Luis Moral
- Pediatric Allergy and Respiratory UnitHospital Universitario Dr. Balmis, ISABIALAlicanteSpain
| | - Teresa Toral
- Pediatric Allergy and Respiratory UnitHospital Universitario Dr. Balmis, ISABIALAlicanteSpain
| | - Mónica Antón
- Allergy ServiceUniversity Hospital VinalopóElche, AlicanteSpain
| | - Carmen Andreu
- Allergy ServiceHospital Vega BajaOrihuela, AlicanteSpain
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Crespo-García T, Cámara-Checa A, Dago M, Rubio-Alarcón M, Rapún J, Tamargo J, Delpón E, Caballero R. Regulation of cardiac ion channels by transcription factors: Looking for new opportunities of druggable targets for the treatment of arrhythmias. Biochem Pharmacol 2022; 204:115206. [PMID: 35963339 DOI: 10.1016/j.bcp.2022.115206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2022] [Revised: 08/04/2022] [Accepted: 08/05/2022] [Indexed: 11/29/2022]
Abstract
Cardiac electrical activity is governed by different ion channels that generate action potentials. Acquired or inherited abnormalities in the expression and/or function of ion channels usually result in electrophysiological changes that can cause cardiac arrhythmias. Transcription factors (TFs) control gene transcription by binding to specific DNA sequences adjacent to target genes. Linkage analysis, candidate-gene screening within families, and genome-wide association studies have linked rare and common genetic variants in the genes encoding TFs with genetically-determined cardiac arrhythmias. Besides its critical role in cardiac development, recent data demonstrated that they control cardiac electrical activity through the direct regulation of the expression and function of cardiac ion channels in adult hearts. This narrative review summarizes some studies showing functional data on regulation of the main human atrial and ventricular Na+, Ca2+, and K+ channels by cardiac TFs such as Pitx2c, Tbx20, Tbx5, Zfhx3, among others. The results have improved our understanding of the mechanisms regulating cardiac electrical activity and may open new avenues for therapeutic interventions in cardiac acquired or inherited arrhythmias through the identification of TFs as potential drug targets. Even though TFs have for a long time been considered as 'undruggable' targets, advances in structural biology have led to the identification of unique pockets in TFs amenable to be targeted with small-molecule drugs or peptides that are emerging as novel therapeutic drugs.
Collapse
Affiliation(s)
- T Crespo-García
- Department of Pharmacology and Toxicology. School of Medicine. Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Gregorio Marañón. CIBERCV, 28040 Madrid, Spain
| | - A Cámara-Checa
- Department of Pharmacology and Toxicology. School of Medicine. Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Gregorio Marañón. CIBERCV, 28040 Madrid, Spain
| | - M Dago
- Department of Pharmacology and Toxicology. School of Medicine. Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Gregorio Marañón. CIBERCV, 28040 Madrid, Spain
| | - M Rubio-Alarcón
- Department of Pharmacology and Toxicology. School of Medicine. Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Gregorio Marañón. CIBERCV, 28040 Madrid, Spain
| | - J Rapún
- Department of Pharmacology and Toxicology. School of Medicine. Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Gregorio Marañón. CIBERCV, 28040 Madrid, Spain
| | - J Tamargo
- Department of Pharmacology and Toxicology. School of Medicine. Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Gregorio Marañón. CIBERCV, 28040 Madrid, Spain
| | - E Delpón
- Department of Pharmacology and Toxicology. School of Medicine. Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Gregorio Marañón. CIBERCV, 28040 Madrid, Spain.
| | - R Caballero
- Department of Pharmacology and Toxicology. School of Medicine. Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Gregorio Marañón. CIBERCV, 28040 Madrid, Spain
| | -
- Department of Pharmacology and Toxicology. School of Medicine. Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Gregorio Marañón. CIBERCV, 28040 Madrid, Spain
| |
Collapse
|
9
|
Lorenzo-Gómez MF, Foley S, Nickel JC, García-Cenador MB, Padilla-Fernández BY, González-Casado I, Martínez-Huélamo M, Yang B, Blick C, Ferreira F, Caballero R, Saz-Leal P, Casanovas M. Sublingual MV140 for Prevention of Recurrent Urinary Tract Infections. NEJM Evid 2022; 1:EVIDoa2100018. [PMID: 38319200 DOI: 10.1056/evidoa2100018] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2024]
Abstract
Sublingual MV140 for Prevention of Recurrent UTIThis randomized placebo-controlled trial tested MV140, a sublingual preparation of whole-cell inactivated bacteria, in women with recurrent urinary tract infection (UTI). MV140 administered sublingually for either 3 or 6 months decreased UTI incidence and prevented recurrence for up to 1 year compared with placebo, without serious adverse events.
Collapse
Affiliation(s)
| | - Stephen Foley
- Department of Urology, Royal Berkshire Hospital, Reading, United Kingdom
| | - J Curtis Nickel
- Department of Urology, Queen's University, Kingston, ON, Canada
| | | | | | | | | | - Bob Yang
- Department of Urology, Royal Berkshire Hospital, Reading, United Kingdom
| | - Christopher Blick
- Department of Urology, Royal Berkshire Hospital, Reading, United Kingdom
| | | | | | - Paula Saz-Leal
- Medical Department, Inmunotek S.L., Alcalá de Henares, Spain
| | | |
Collapse
|
10
|
Caballero R, Grau A, Javaloyes G, Del Pozo S, León MÁ, Romero M, Casanovas M. Combination of Allergic Asthma Symptom and Medication Scores in Allergen Immunotherapy Trials: A Proposal. Int Arch Allergy Immunol 2021; 182:571-573. [PMID: 33498057 DOI: 10.1159/000513543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Accepted: 11/27/2020] [Indexed: 11/19/2022] Open
|
11
|
Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Turner N, Ciruelos EM, Muñoz M, Bermejo B, Margeli M, Anton A, Kahan Z, Csöszi T, Casas MI, Murillo L, Morales S, Alba E, Gal-Yam E, Guerrero-Zotano A, Calvo L, de la Haba-Rodriguez J, Ramos M, Alvarez I, Garcia-Palomo A, Huang Bartlett C, Koehler M, Caballero R, Corsaro M, Huang X, Garcia-Sáenz JA, Chacón JI, Swift C, Thallinger C, Gil-Gil M. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. Ann Oncol 2020; 32:488-499. [PMID: 33385521 DOI: 10.1016/j.annonc.2020.12.013] [Citation(s) in RCA: 60] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2020] [Revised: 12/16/2020] [Accepted: 12/17/2020] [Indexed: 01/23/2023] Open
Abstract
BACKGROUND Palbociclib plus endocrine therapy (ET) is the standard treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative, metastatic breast cancer (MBC). However, its efficacy has not been compared with that of chemotherapy in a phase III trial. PATIENTS AND METHODS PEARL is a multicentre, phase III randomised study in which patients with aromatase inhibitor (AI)-resistant MBC were included in two consecutive cohorts. In cohort 1, patients were randomised 1 : 1 to palbociclib plus exemestane or capecitabine. On discovering new evidence about estrogen receptor-1 (ESR1) mutations inducing resistance to AIs, the trial was amended to include cohort 2, in which patients were randomised 1 : 1 between palbociclib plus fulvestrant and capecitabine. The stratification criteria were disease site, prior sensitivity to ET, prior chemotherapy for MBC, and country of origin. Co-primary endpoints were progression-free survival (PFS) in cohort 2 and in wild-type ESR1 patients (cohort 1 + cohort 2). ESR1 hotspot mutations were analysed in baseline circulating tumour DNA. RESULTS From March 2014 to July 2018, 296 and 305 patients were included in cohort 1 and cohort 2, respectively. Palbociclib plus ET was not superior to capecitabine in both cohort 2 [median PFS: 7.5 versus 10.0 months; adjusted hazard ratio (aHR): 1.13; 95% confidence interval (CI): 0.85-1.50] and wild-type ESR1 patients (median PFS: 8.0 versus 10.6 months; aHR: 1.11; 95% CI: 0.87-1.41). The most frequent grade 3-4 toxicities with palbociclib plus exemestane, palbociclib plus fulvestrant and capecitabine, respectively, were neutropenia (57.4%, 55.7% and 5.5%), hand/foot syndrome (0%, 0% and 23.5%), and diarrhoea (1.3%, 1.3% and 7.6%). Palbociclib plus ET offered better quality of life (aHR for time to deterioration of global health status: 0.67; 95% CI: 0.53-0.85). CONCLUSIONS There was no statistical superiority of palbociclib plus ET over capecitabine with respect to PFS in MBC patients resistant to AIs. Palbociclib plus ET showed a better safety profile and improved quality of life.
Collapse
Affiliation(s)
- M Martin
- Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Medicine Department, Universidad Complutense, Madrid, Spain; Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain.
| | - C Zielinski
- Medical Oncology, Central European Cancer Center, Wiener Privatklinik Hospital, Vienna, Austria; CECOG Central European Cooperative Oncology Group, Vienna, Austria
| | - M Ruiz-Borrego
- GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Universitario Virgen del Rocio, Sevilla, Spain
| | - E Carrasco
- GEICAM Spanish Breast Cancer Group, Madrid, Spain
| | - N Turner
- Institute of Cancer Research and Royal Marsden, London, UK
| | - E M Ciruelos
- GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain; Medical Oncology, HM Hospitales Madrid, Madrid, Spain; SOLTI Group on Breast Cancer Research, Barcelona, Spain
| | - M Muñoz
- GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors (IDIBAPS), Barcelona, Spain
| | - B Bermejo
- Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain; Biomedical Research Institute INCLIVA, Valencia, Spain
| | - M Margeli
- GEICAM Spanish Breast Cancer Group, Madrid, Spain; B-ARGO Group, Catalan Institute of Oncology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | - A Anton
- Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain
| | - Z Kahan
- Department of Oncotherapy, University of Szeged, Szeged, Hungary
| | - T Csöszi
- Department of Oncology, Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelőintezet, Szolnok, Hungary
| | - M I Casas
- GEICAM Spanish Breast Cancer Group, Madrid, Spain
| | - L Murillo
- GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Clínico de Zaragoza Lozano Blesa, Zaragoza, Spain
| | - S Morales
- GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Universitario Arnau de Vilanova, Lleida, Spain
| | - E Alba
- Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; UGCI Medical Oncology, Hospitales Regional y Virgen de la Victoria, IBIMA, Málaga, Spain
| | - E Gal-Yam
- Department of Oncology, Institute of Oncology, Sheba Medical Center, Tel-Hashomer, Israel
| | - A Guerrero-Zotano
- GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain
| | - L Calvo
- GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Complejo Hospitalario A Coruña, Coruña, Spain
| | - J de la Haba-Rodriguez
- Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Universitario Reina Sofia, Córdoba; Instituto Maimonides de Investigación Biomédica (IMIBIC); Universidad de Córdoba, Córdoba, Spain
| | - M Ramos
- GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro Oncológico de Galicia, A Coruña, Coruña, Spain
| | - I Alvarez
- GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Universitario Donostia-Biodonostia, San Sebastián, Spain
| | - A Garcia-Palomo
- GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital de León, León, Spain
| | | | - M Koehler
- Pfizer, USA; Repare Therapeutics, Cambridge, USA
| | - R Caballero
- GEICAM Spanish Breast Cancer Group, Madrid, Spain
| | | | | | - J A Garcia-Sáenz
- GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Clínico Universitario San Carlos, Madrid, Spain
| | - J I Chacón
- GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Virgen de la Salud, Toledo, Spain
| | - C Swift
- Ralph Lauren Centre for Breast Cancer Research, Royal Marsden, London, UK
| | - C Thallinger
- CECOG Central European Cooperative Oncology Group, Vienna, Austria; Department of Oncology, Medical University of Vienna, Department of Oncology, Vienna, Austria
| | - M Gil-Gil
- GEICAM Spanish Breast Cancer Group, Madrid, Spain; Institut Català d'Oncologia (ICO) & IDIBELL, L'Hospitalet, Barcelona, Spain
| |
Collapse
|
12
|
Quintanar C, Caballero R, Ugalde M, Ramos M, Chavira E, Cruz-Manjarrez H, Espinosa F. Charge transfer and hydrogen adsorption in the Pd/Ag bimetallic nano system: an experimental and theoretical DFT cluster approach. Mol Phys 2020. [DOI: 10.1080/00268976.2020.1820090] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- C. Quintanar
- Departamento de Física, Facultad de Ciencias, Universidad Nacional Autónoma de México, México México
| | - R. Caballero
- Departamento de Física, Facultad de Ciencias, Universidad Nacional Autónoma de México, México México
| | - M. Ugalde
- Banco de México, Evaluación de Insumos, Irrigación México
| | - M. Ramos
- Universidad Nacional Autónoma de México, Instituto de Investigaciones en Materiales, México México
| | - E. Chavira
- Universidad Nacional Autónoma de México, Instituto de Investigaciones en Materiales, México México
| | - H. Cruz-Manjarrez
- Universidad Nacional Autónoma de México, Instituto de Física, México México
| | - F. Espinosa
- Centro de Investigación en Materiales Avanzados, Física de Materiales, Chihuahua México
| |
Collapse
|
13
|
López-Alcorocho JM, Aboli L, Rodríguez-Iñigo E, Guillén-Vicente I, Guillén-Vicente M, Caballero R, Casqueiro M, Fernández-Jaen TF, Abelow S, Guillen-García P. Clinical outcome and subchondral bone edema presence at two-year follow-up after high density autologous chondrocyte implantation treatment in the knee. Rev Esp Cir Ortop Traumatol (Engl Ed) 2019; 63:253-260. [PMID: 31147299 DOI: 10.1016/j.recot.2019.03.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2018] [Revised: 02/01/2019] [Accepted: 03/10/2019] [Indexed: 10/26/2022] Open
Abstract
BACKGROUND Recently, a new approach of autologous chondrocyte implantation technique (using as biomaterial a collagen type i/iii membrane) based on increasing cell density called HD-ACI (High Density Autologous Chondrocyte Implantation) has been described. The objective of this paper was to study the clinical outcome and incidence of subchondral bone oedema in patients with cartilage lesions in the knee treated with HD-ACI at 1-2 years of follow-up. METHODS This is a retrospective study performed with forty patients with chondral injuries grade iii-iv. All patients were treated with HD-ACI with a cellular dose of 5×106 chondrocytes /cm2 of lesion. The subjective perception of improvement of symptoms and functionality was measured with the IKDC score (International Knee Documentation Committee). The presence of bone oedema was assessed at 6, 12 and 24 months of follow-up by magnetic resonance imaging. RESULTS IKDC values showed a significant improvement at 12 and 24 months (P<.001). The mean difference of IKDC between the baseline visit and 12 months was 26.3 points, and 31.6 points at 24 months. Twenty-seven point five percent of the patients presented subchondral bone oedema at 2 years of follow-up. CONCLUSIONS HD-ACI is an effective and safe treatment that improves pain, clinical perception and functionality of the joint. No correlation was found between the presence of bone oedema and the patients' clinical outcome.
Collapse
Affiliation(s)
- J M López-Alcorocho
- Unidad de Investigación y Departamento de Traumatología, Cínica CEMTRO, Madrid, España.
| | - L Aboli
- Unidad de Investigación y Departamento de Traumatología, Cínica CEMTRO, Madrid, España
| | - E Rodríguez-Iñigo
- Unidad de Investigación y Departamento de Traumatología, Cínica CEMTRO, Madrid, España
| | - I Guillén-Vicente
- Unidad de Investigación y Departamento de Traumatología, Cínica CEMTRO, Madrid, España
| | - M Guillén-Vicente
- Unidad de Investigación y Departamento de Traumatología, Cínica CEMTRO, Madrid, España
| | - R Caballero
- Unidad de Investigación y Departamento de Traumatología, Cínica CEMTRO, Madrid, España
| | - M Casqueiro
- Unidad de Investigación y Departamento de Traumatología, Cínica CEMTRO, Madrid, España
| | - T F Fernández-Jaen
- Unidad de Investigación y Departamento de Traumatología, Cínica CEMTRO, Madrid, España
| | - S Abelow
- Unidad de Investigación y Departamento de Traumatología, Cínica CEMTRO, Madrid, España
| | - P Guillen-García
- Unidad de Investigación y Departamento de Traumatología, Cínica CEMTRO, Madrid, España
| |
Collapse
|
14
|
Alba E, Rueda OM, Lluch A, Albanell J, Chin SF, Chacón JI, Calvo L, De la Haba-Rodriguez J, Bermejo B, Ribelles N, Sánchez-Rovira P, Plazaola A, Barnadas A, Cirauqul B, Ramos M, Arcusa A, Carrasco E, Herranz J, Chiesa M, Caballero R, Santonja A, Rojo F, Caldas C. Abstract P5-12-03: Genome copy number entropy as predictor of response for neoadjuvant therapy in early breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-12-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Copy Number Alterations (CNAs) represent changes in the copy number of genomic segments of somatic cells due to chromosomal instability. CNAs include gene amplifications or deletions and can be involved in tumorigenesis. We analyzed CNAs data in pre- and post-treatment (ttm) tumors from patients (pts) with early breast cancer (BC) in the neoadjuvant trials GEICAM/2006-03 and GEICAM/2006-14, with the aim to identify CNAs in particular genomic regions (genetic entropy) associated with treatment response.
Methods
GEICAM/2006-03 (NCT00432172) HER2-negative pts were selectively treated according to clinical subtypes: triple negative (TN) pts were treated with standard anthracycline/taxane -based chemotherapy (AT-CT) +/- carboplatin, while luminal patients were randomized to AT-CT vs. hormonotherapy; GEICAM/2006-14 (NCT00841828) HER2+ pts received AT-CT plus anti-HER2 therapy.Shallow-whole genome Illumina sequencing DNA data from 204 paraffin-embedded tumors (100 pre- and 104 post-ttm) were segmented to obtain CNAs and recurrent altered genomic regions were defined. We used Wilcoxon test to analyze the frequency of altered regions and logistic regression analyses to explore their association with tumor response, in terms of pathological complete response (pCR) in breast and axilla. Validation of altered genes associated with therapy response was performed in the microarray gene expression-based Hatzis dataset (GSE25066) from pts receiving neoadjuvant AT-CT (1).
Results
A total of 672 regions covering the whole genome were identified upon analysis of CNAs data. Regions were categorized according to their alteration status as amplified, normal and lost. Comparative analysis of alterations revealed 11 regions significantly different (p<0.05) in pre- vs post-ttm tumors. Logistic regression analysis showed that in pre-ttm tumors specific alterations of 8 regions localized in 3 different genomic loci (11q12, 16q22 and 21q22) were significantly associated with pCR (p<0.05). Independent analyses of CNAs data with “CGH regions” and “GISTIC2.0” tools confirmed the special relevance of 2 of these 8 regions (#653 and #654), amplified in the locus 21q22.12. This locus contains 20 genes whose expression was tested in Hatzis dataset (1) (GSE25066): the analysis showed that overexpression of 5 of these 20 genes (CHAF1B, CBR1, CBR3, RCAN1 and SLC5A3) turned out to be significantly higher in the cohort of pts who reached pCR, in agreement with our findings. Some of these genes have already been described as proliferation markers (CHAF1B) or involved in treatment response (CBR1) in BC. Other genes related to BC in this genomic region are the transcription factor RUNX1 and the Lysine Methyltransferase SETD4.
Conclusions
According to our results, neoadjuvant therapy can modulate genomic aberrations landscape in BC. Our data suggest that amplification of specific genes in the genomic locus (21q22.12) is involved in the neoadjuvant therapy response in early BC.
(1): Hatzis et al., JAMA 2011, 305(18) 1873-81
Citation Format: Alba E, Rueda OM, Lluch A, Albanell J, Chin S-F, Chacón JI, Calvo L, De la Haba-Rodriguez J, Bermejo B, Ribelles N, Sánchez-Rovira P, Plazaola A, Barnadas A, Cirauqul B, Ramos M, Arcusa A, Carrasco E, Herranz J, Chiesa M, Caballero R, Santonja A, Rojo F, Caldas C. Genome copy number entropy as predictor of response for neoadjuvant therapy in early breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-12-03.
Collapse
Affiliation(s)
- E Alba
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - OM Rueda
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - A Lluch
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - J Albanell
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - S-F Chin
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - JI Chacón
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - L Calvo
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - J De la Haba-Rodriguez
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - B Bermejo
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - N Ribelles
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - P Sánchez-Rovira
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - A Plazaola
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - A Barnadas
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - B Cirauqul
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - M Ramos
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - A Arcusa
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - E Carrasco
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - J Herranz
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - M Chiesa
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - R Caballero
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - A Santonja
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - F Rojo
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| | - C Caldas
- Instituto de Investigación Biomédica de Málaga (IBIMA) - Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) - H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; Onkologikoa, San Sebastián, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spai
| |
Collapse
|
15
|
Quiroga V, Holgado E, Alonso J, Andres R, Moreno Anton F, Alamo De La Gala M, Henao F, Cirauqui Cirauqui B, Margeli M, Cortes Castan J, Gion Cortes M, Soto A, Benito S, Escudero M, Chiesa M, Caballero R, Bezares Montes S, Carrasco E, De La Cruz Merino L. Run-in-phase results from a multicenter phase II trial to evaluate pembrolizumab (P) and gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 PANGEA-Breast. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy487.019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Purcell C, Batke SP, Yiotis C, Caballero R, Soh WK, Murray M, McElwain JC. Increasing stomatal conductance in response to rising atmospheric CO2. Ann Bot 2018; 121:1427. [PMID: 29471375 PMCID: PMC6007760 DOI: 10.1093/aob/mcy023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
|
17
|
Purcell C, Batke SP, Yiotis C, Caballero R, Soh WK, Murray M, McElwain JC. Increasing stomatal conductance in response to rising atmospheric CO2. Ann Bot 2018; 121:1137-1149. [PMID: 29394303 PMCID: PMC5946907 DOI: 10.1093/aob/mcx208] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Accepted: 12/16/2017] [Indexed: 05/19/2023]
Abstract
Background and Aims Studies have indicated that plant stomatal conductance (gs) decreases in response to elevated atmospheric CO2, a phenomenon of significance for the global hydrological cycle. However, gs increases across certain CO2 ranges have been predicted by optimization models. The aim of this work was to demonstrate that under certain environmental conditions, gs can increase in response to elevated CO2. Methods Using (1) an extensive, up-to-date synthesis of gs responses in free air CO2 enrichment (FACE)experiments, (2) in situ measurements across four biomes showing dynamic gs responses to a CO2 rise of ~50 ppm (characterizing the change in this greenhouse gas over the past three decades) and (3) a photosynthesis-stomatal conductance model, it is demonstrated that gs can in some cases increase in response to increasing atmospheric CO2. Key Results Field observations are corroborated by an extensive synthesis of gs responses in FACE experiments showing that 11.8 % of gs responses under experimentally elevated CO2 are positive. They are further supported by a strong data-model fit (r2 = 0.607) using a stomatal optimization model applied to the field gs dataset. A parameter space identified in the Farquhar-Ball-Berry photosynthesis-stomatal conductance model confirms field observations of increasing gs under elevated CO2 in hot dry conditions. Contrary to the general assumption, positive gs responses to elevated CO2, although relatively rare, are a feature of woody taxa adapted to warm, low-humidity conditions, and this response is also demonstrated in global simulations using the Community Land Model (CLM4). Conclusions The results contradict the over-simplistic notion that global vegetation always responds with decreasing gs to elevated CO2, a finding that has important implications for predicting future vegetation feedbacks on the hydrological cycle at the regional level.
Collapse
Affiliation(s)
- C Purcell
- School of Biology and Environmental Science, Earth Institute, University College Dublin, Belfield, Dublin, Ireland
| | - S P Batke
- School of Biology and Environmental Science, Earth Institute, University College Dublin, Belfield, Dublin, Ireland
- Department of Biology, Edge Hill University, St. Helens Road, Ormskirk, UK
| | - C Yiotis
- School of Biology and Environmental Science, Earth Institute, University College Dublin, Belfield, Dublin, Ireland
| | - R Caballero
- Department of Meteorology and Bolin Centre for Climate Research, Stockholm University, Stockholm, Sweden
| | - W K Soh
- School of Biology and Environmental Science, Earth Institute, University College Dublin, Belfield, Dublin, Ireland
| | - M Murray
- School of Biology and Environmental Science, Earth Institute, University College Dublin, Belfield, Dublin, Ireland
| | - J C McElwain
- Botany Department, Trinity College Dublin, College Green, Dublin, Ireland
| |
Collapse
|
18
|
Ethier JL, Ocaña A, Rodríguez Lescure A, Ruíz A, Alba E, Calvo L, Ruíz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Ramos M, Gracia Marco J, Lluch A, Álvarez I, Casas M, Sánchez-Aragó M, Carrasco E, Caballero R, Amir E, Martin M. Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study. Eur J Cancer 2018; 94:199-205. [PMID: 29573665 DOI: 10.1016/j.ejca.2018.02.018] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2017] [Revised: 02/15/2018] [Accepted: 02/15/2018] [Indexed: 10/17/2022]
Abstract
BACKGROUND Retrospective data suggest better outcomes for patients with double hormonal receptor (oestrogen [ER] and progesterone receptor [PgR])-positive (dHR+) early breast cancer, compared with single hormonal receptor-positive, sHR+, (ER+/PgR- or ER-/PgR+) disease. Here, we evaluate the classification according to intrinsic subtypes and clinical outcomes of sHR+ versus dHR+ in HER2-negative breast cancer patients enrolled in GEICAM/9906 study (NCT00129922). METHODS Archival tumours were retrieved retrospectively for the analysis of ER, PgR and HER2 status and classified into intrinsic subtypes using the PAM50 gene expression assay. Disease-free survival (DFS) and overall survival (OS) were explored using a Cox proportional hazard analysis. RESULTS Data on intrinsic subtypes were available in 571 (50%) patients with ER+ and/or PR+, and HER2-negative primary tumours. The incidence of luminal A and luminal B subtypes were 52%/36% in dHR+ tumours (ER+/PgR+), and 15%/58% in ER+/PgR-tumours. ER-/PgR+ tumours were mainly luminal A (52%). Compared with ER+/PgR+ patients, DFS was similar in ER-/PgR+ (hazard ratio [HR] 1.15, 95% confidence interval [CI] 0.57-2.34, p = 0.70) but worse in ER+/PgR- patients (HR 1.60, 95% CI 1.12-2.28, p < 0.01). Similar results were observed for OS (HR 1.50, p = 0.30 and HR 1.86, p < 0.01, respectively). CONCLUSIONS The ER+/PgR- group is characterised by higher proliferation and worse outcomes. In spite of the ER-/PgR+ subgroup resembles ER+/PgR+ disease in terms of molecular subtypes and outcomes, the small number of patients in this subgroup prevents from drawing any conclusions. TRIAL REGISTRATION EudraCT: 2005-003108-12 (retrospectively registered 28/06/2005). CLINICALTRIALS. GOV IDENTIFIER NCT00129922 (retrospectively registered 10/08/2005).
Collapse
Affiliation(s)
- J L Ethier
- Department of Medical Oncology, Kingston Health Sciences Centre, Queen's University, Kingston, Ontario, Canada
| | - A Ocaña
- Complejo Hospitalario de Albacete, Albacete, Spain; GEICAM (Spanish Breast Cancer Group), Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Spain
| | - A Rodríguez Lescure
- GEICAM (Spanish Breast Cancer Group), Spain; Hospital Universitario de Elche, Elche, Spain
| | - A Ruíz
- GEICAM (Spanish Breast Cancer Group), Spain; Instituto Valenciano de Oncología, Valencia, Spain
| | - E Alba
- GEICAM (Spanish Breast Cancer Group), Spain; Hospital Virgen de La Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Spain
| | - L Calvo
- GEICAM (Spanish Breast Cancer Group), Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
| | - M Ruíz-Borrego
- GEICAM (Spanish Breast Cancer Group), Spain; Hospital Univ. Virgen Del Rocío, Sevilla, Spain
| | - A Santaballa
- GEICAM (Spanish Breast Cancer Group), Spain; Hospital Universitario La Fe, Valencia, Spain
| | - C A Rodríguez
- GEICAM (Spanish Breast Cancer Group), Spain; Hospital Clínico Universitario de Salamanca, Salamanca (IBSAL), Spain
| | - C Crespo
- GEICAM (Spanish Breast Cancer Group), Spain; Hospital Ramón y Cajal, Madrid, Spain
| | - M Ramos
- GEICAM (Spanish Breast Cancer Group), Spain; Centro Oncológico de Galicia, A Coruña, Spain
| | - J Gracia Marco
- GEICAM (Spanish Breast Cancer Group), Spain; Hospital de Cabueñes, Gijón, Spain
| | - A Lluch
- GEICAM (Spanish Breast Cancer Group), Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Spain; Hospital Clínico Universitario de Valencia, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain
| | - I Álvarez
- GEICAM (Spanish Breast Cancer Group), Spain; Hospital de Donostia, San Sebastián, Spain
| | - M Casas
- GEICAM (Spanish Breast Cancer Group), Spain
| | | | - E Carrasco
- GEICAM (Spanish Breast Cancer Group), Spain
| | | | - E Amir
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada
| | - M Martin
- GEICAM (Spanish Breast Cancer Group), Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
| |
Collapse
|
19
|
Martín M, Hoffman J, Ruiz-Borrego M, Muñoz M, Calvo L, Crownover P, García-Sáenz JA, Alba E, Wang D, Thallinger C, Stradella A, Montaño Á, Adamo B, Antolín S, Moreno-Antón F, Falo C, Ruiz V, Martín N, Caballero R, Carrasco E, Gil-Gil M. Abstract P5-21-23: Evaluation of the drug interaction potential of palbociclib and exemestane – Results from the PEARL pharmacokinetic sub-Study. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-21-23] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Palbociclib (PAL) is an oral cyclin-dependent kinase (CDK) 4/6 inhibitor that is under investigation in multiple oncologic clinical trials and is currently approved for use in combination with aromatase inhibitors (AIs) or fulvestrant (FUL) in patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2–) advanced breast cancer (BC).
The PEARL Study is an ongoing international, open label, controlled, randomized Phase 3 study comparing the efficacy and safety of PAL in combination with endocrine therapy (exemestane [EXE] or FUL) versus capecitabine in postmenopausal women with HR+/ HER2– metastatic BC whose disease progressed on AIs. A secondary objective of the study was to evaluate the pharmacokinetics (PK) of PAL (125mg QD, 3 weeks on/1 week off) and EXE (25mg QD, continuously) when coadministered. This is the first study to investigate the drug-drug interaction (DDI) potential of the combination of PAL and the AI EXE.
Methods: Patients (pts) randomized to the PAL+EXE arm of the PEARL Study in seven selected sites had the option of participating in the PK sub-study. Those who enrolled in the PK sub-study received EXE alone in a 7-day lead-in period immediately prior to Cycle 1 Day 1, when both drugs were coadministered on their standard dosing regimens. Sub-study pts were to have 2 pre-dose plasma PK samples drawn at steady-state (ss) during the lead-in period ("EXE Alone") for EXE determination, and 2 ss PK samples drawn for EXE and PAL determination (2 per analyte) during coadministration ("PAL+EXE"). Plasma concentrations of PAL and EXE were measured using validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods. The withinpatient mean concentration of the PK samples which met ss acceptance criteria (WPM-Ctrough) for each analyte were generated for each treatment period as the input for DDI analyses.
To assess the effect of coadministration of PAL on EXE PK, the WPM-Ctrough of EXE was compared within patients between the "PAL+EXE" (Test) and "EXE Alone" (Reference) treatment periods using a one-way analysis of variance (ANOVA) model with treatment as a fixed effect and patient as a random effect. To assess the effect of coadministration of EXE on PAL PK, the WPM-Ctrough of PAL was compared between the "PAL+EXE" period (Test) and historical data (Reference) using an ANOVA model. Analysis of covariance (ANCOVA) models were used to assess the impact of demographic differences between analysis populations in covariates known to impact PAL PK on the ANOVA model conclusions.
Results: A total of 26 pts randomized to the PAL+EXE arm were enrolled in the PK sub-study and had PK samples analysed, of which 23 meet ss acceptance criteria. The ratio of the adjusted geometric means for EXE WPM-Ctrough was 106.9% (90%CI: 82.4-138.8), when EXE was administered with PAL, compared with its administration alone. Likewise, the models to assess potential for EXE to perpetrate DDI on PAL PK showed ratios of adjusted geometric means of 102.4% (90%CI: 82.0-127.9) and 111.6% (90%CI: 90.3137.8), when adjusted for covariates.
Conclusion: The PK data indicate a lack of a clinically meaningful DDI between PAL and EXE when the 2 drugs are coadministered.
Sponsor: GEICAM
Citation Format: Martín M, Hoffman J, Ruiz-Borrego M, Muñoz M, Calvo L, Crownover P, García-Sáenz JA, Alba E, Wang D, Thallinger C, Stradella A, Montaño Á, Adamo B, Antolín S, Moreno-Antón F, Falo C, Ruiz V, Martín N, Caballero R, Carrasco E, Gil-Gil M. Evaluation of the drug interaction potential of palbociclib and exemestane – Results from the PEARL pharmacokinetic sub-Study [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-21-23.
Collapse
Affiliation(s)
- M Martín
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - J Hoffman
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - M Ruiz-Borrego
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - M Muñoz
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - L Calvo
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - P Crownover
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - JA García-Sáenz
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - E Alba
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - D Wang
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - C Thallinger
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - A Stradella
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - Á Montaño
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - B Adamo
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - S Antolín
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - F Moreno-Antón
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - C Falo
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - V Ruiz
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - N Martín
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - R Caballero
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - E Carrasco
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - M Gil-Gil
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| |
Collapse
|
20
|
de la Cruz L, Sánchez-Margalet V, Berraondo P, Benito S, Escudero MJ, Caballero R, Carrasco E, Galluzzi L, Rojo F. Abstract OT1-01-02: A multicenter phase II trial to evaluate the efficacy and safety of pembrolizumab and gemcitabine in patients with HER2-negative advanced breast cancer: GEICAM/2015-04 PANGEA-Breast. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot1-01-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Treatment options for advanced breast cancer (ABC) are multiple but unable to properly respond to current clinical needs. In particular, improved therapies are needed for triple negative and hormone receptor (HR)-positive but heavily pretreated patients. Pembrolizumab (P) is a human monoclonal antibody that blocks the PD-1/PD-L1 interaction hence potentiates anticancer T cell responses. Gemcitabine (G) is a cytotoxic drug with well-known immunostimulatory properties. Here, we report an ongoing phase II clinical trial to identify the Recommended Phase II Dose (RP2D) and the efficacy of the combination of these two agents in ABC patients. We hypothesize that these agents may synergize to induce responses with long term clinical benefit (ClinicalTrials.gov Identifier: NCT03025880).
Trial Design:
Eligible patients are HER2-negative ABC patients who received prior treatment with anthracyclines and taxanes and two or more prior lines of hormone therapy, if HR-positive disease. Patients with CNS involvement are also eligible if clinically stable. Treatment consists of 21-day cycles with 200 mg P on day 1 and G on days 1 and 8. In the safety dose testing, we use a standard 6+6 design with 2 dose levels (DL) of G: 1250 mg/m2 (DL0) and 1000 mg/m2 (DL1). Patients are treated until radiologic or symptomatic progression, or unacceptable toxicity. The primary objectives are RP2D and objective response rate (ORR) of the combination; secondary objectives include evaluation of safety and tolerability and other efficacy variables (progression-free survival [PFS], clinical benefit rate [CBR], response duration [RD] and overall survival [OS]). Efficacy is measured by RECIST 1.1. and irRECIST. Safety is measured using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) 4.0. As exploratory objectives, immunological biomarkers are analyzed in tumor biopsies and blood samples and correlated with (1) clinical efficacy and (2) disease outcomes.Sequential tumor samples are collected at baseline, cycle 3 and at progression. Blood samples are drawn at baseline, cycle 3, and cycle 6, or at post-treatment visit (whatever occurs first). Tumor samples are characterized for intratumoral and stromal tumor-infiltrating lymphocytes, tumor-associated macrophages and myeloid-derived suppressor cells, PD-L1 expression in tumor cells and stroma. Moreover, molecular and genetic profiling will be performed. Blood samples are characterized for peripheral blood mononuclear cell (PBMC) phenotype (including expression of co-activatory and co-inhibitory receptors), cytokine profile, and activity of other immunosuppressive pathways (e.g., IDO1-dependent tryptophan catabolism). These results will be compared with data from a cohort of healthy volunteers.
A maximum of 65 patients will be included. The study is approved by the ethical committee and Competent Authority of Spain and already open for patient recruitment in 2 of the 10 participating sites.
Keywords:
Breast
HER2 negative
Pembrolizumab
Immunotherapy
Citation Format: de la Cruz L, Sánchez-Margalet V, Berraondo P, Benito S, Escudero MJ, Caballero R, Carrasco E, Galluzzi L, Rojo F. A multicenter phase II trial to evaluate the efficacy and safety of pembrolizumab and gemcitabine in patients with HER2-negative advanced breast cancer: GEICAM/2015-04 PANGEA-Breast [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT1-01-02.
Collapse
Affiliation(s)
- L de la Cruz
- Hospital Universitario Virgen de la Macarena, GEICAM Spanish Breast Cancer Group, Sevilla, Spain; Centro de Investigación Medica Aplicada (CIMA), Pamplona, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Weill Cornell Medical College, Sandra and Edward Meyer Cancer Center, Université Paris Descartes/Paris V, NY; IIS-Fundacion Jimenez Diaz-UAM. GEICAM Spanish Breast Cancer Group, Madrid, Spain
| | - V Sánchez-Margalet
- Hospital Universitario Virgen de la Macarena, GEICAM Spanish Breast Cancer Group, Sevilla, Spain; Centro de Investigación Medica Aplicada (CIMA), Pamplona, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Weill Cornell Medical College, Sandra and Edward Meyer Cancer Center, Université Paris Descartes/Paris V, NY; IIS-Fundacion Jimenez Diaz-UAM. GEICAM Spanish Breast Cancer Group, Madrid, Spain
| | - P Berraondo
- Hospital Universitario Virgen de la Macarena, GEICAM Spanish Breast Cancer Group, Sevilla, Spain; Centro de Investigación Medica Aplicada (CIMA), Pamplona, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Weill Cornell Medical College, Sandra and Edward Meyer Cancer Center, Université Paris Descartes/Paris V, NY; IIS-Fundacion Jimenez Diaz-UAM. GEICAM Spanish Breast Cancer Group, Madrid, Spain
| | - S Benito
- Hospital Universitario Virgen de la Macarena, GEICAM Spanish Breast Cancer Group, Sevilla, Spain; Centro de Investigación Medica Aplicada (CIMA), Pamplona, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Weill Cornell Medical College, Sandra and Edward Meyer Cancer Center, Université Paris Descartes/Paris V, NY; IIS-Fundacion Jimenez Diaz-UAM. GEICAM Spanish Breast Cancer Group, Madrid, Spain
| | - MJ Escudero
- Hospital Universitario Virgen de la Macarena, GEICAM Spanish Breast Cancer Group, Sevilla, Spain; Centro de Investigación Medica Aplicada (CIMA), Pamplona, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Weill Cornell Medical College, Sandra and Edward Meyer Cancer Center, Université Paris Descartes/Paris V, NY; IIS-Fundacion Jimenez Diaz-UAM. GEICAM Spanish Breast Cancer Group, Madrid, Spain
| | - R Caballero
- Hospital Universitario Virgen de la Macarena, GEICAM Spanish Breast Cancer Group, Sevilla, Spain; Centro de Investigación Medica Aplicada (CIMA), Pamplona, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Weill Cornell Medical College, Sandra and Edward Meyer Cancer Center, Université Paris Descartes/Paris V, NY; IIS-Fundacion Jimenez Diaz-UAM. GEICAM Spanish Breast Cancer Group, Madrid, Spain
| | - E Carrasco
- Hospital Universitario Virgen de la Macarena, GEICAM Spanish Breast Cancer Group, Sevilla, Spain; Centro de Investigación Medica Aplicada (CIMA), Pamplona, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Weill Cornell Medical College, Sandra and Edward Meyer Cancer Center, Université Paris Descartes/Paris V, NY; IIS-Fundacion Jimenez Diaz-UAM. GEICAM Spanish Breast Cancer Group, Madrid, Spain
| | - L Galluzzi
- Hospital Universitario Virgen de la Macarena, GEICAM Spanish Breast Cancer Group, Sevilla, Spain; Centro de Investigación Medica Aplicada (CIMA), Pamplona, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Weill Cornell Medical College, Sandra and Edward Meyer Cancer Center, Université Paris Descartes/Paris V, NY; IIS-Fundacion Jimenez Diaz-UAM. GEICAM Spanish Breast Cancer Group, Madrid, Spain
| | - F Rojo
- Hospital Universitario Virgen de la Macarena, GEICAM Spanish Breast Cancer Group, Sevilla, Spain; Centro de Investigación Medica Aplicada (CIMA), Pamplona, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Weill Cornell Medical College, Sandra and Edward Meyer Cancer Center, Université Paris Descartes/Paris V, NY; IIS-Fundacion Jimenez Diaz-UAM. GEICAM Spanish Breast Cancer Group, Madrid, Spain
| |
Collapse
|
21
|
Caballero R, Haass SG, Andres C, Arques L, Oliva F, Izquierdo-Roca V, Romanyuk YE. Effect of Magnesium Incorporation on Solution-Processed Kesterite Solar Cells. Front Chem 2018; 6:5. [PMID: 29435446 PMCID: PMC5790964 DOI: 10.3389/fchem.2018.00005] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2017] [Accepted: 01/10/2018] [Indexed: 12/02/2022] Open
Abstract
The introduction of the alkaline-earth element Magnesium (Mg) into Cu2ZnSn(S,Se)4 (CTZSSe) is explored in view of potential photovoltaic applications. Cu2Zn1−xMgxSn(S,Se)4 absorber layers with variable Mg content x = 0…1 are deposited using the solution approach with dimethyl sulfoxide solvent followed by annealing in selenium atmosphere. For heavy Mg alloying with x = 0.55…1 the phase separation into Cu2SnSe3, MgSe2, MgSe and SnSe2 occurs in agreement with literature predictions. A lower Mg content of x = 0.04 results in the kesterite phase as confirmed by XRD and Raman spectroscopy. A photoluminescence maximum is red-shifted by 0.02 eV as compared to the band-gap and a carrier concentration NCV of 1 × 1016 cm−3 is measured for a Mg-containing kesterite solar cell device. Raman spectroscopy indicates that structural defects can be reduced in Mg-containing absorbers as compared to the Mg-free reference samples, however the best device efficiency of 7.2% for a Mg-containing cell measured in this study is lower than those frequently reported for the conventional Na doping.
Collapse
Affiliation(s)
- Raquel Caballero
- Departamento de Física Aplicada, Universidad Autónoma de Madrid, Madrid, Spain
| | - Stefan G Haass
- Laboratory for Thin Films and Photovoltaics, Empa- Swiss Federal Laboratories for Materials Science and Technology, Dübendorf, Switzerland
| | - Christian Andres
- Laboratory for Thin Films and Photovoltaics, Empa- Swiss Federal Laboratories for Materials Science and Technology, Dübendorf, Switzerland
| | - Laia Arques
- Catalonia Institute for Energy Research (IREC), Barcelona, Spain
| | - Florian Oliva
- Catalonia Institute for Energy Research (IREC), Barcelona, Spain
| | | | - Yaroslav E Romanyuk
- Laboratory for Thin Films and Photovoltaics, Empa- Swiss Federal Laboratories for Materials Science and Technology, Dübendorf, Switzerland
| |
Collapse
|
22
|
Semenenko MO, Babichuk IS, Kyriienko O, Bodnar IV, Caballero R, Leon M. RF Electromagnetic Field Treatment of Tetragonal Kesterite CZTSSe Light Absorbers. Nanoscale Res Lett 2017; 12:408. [PMID: 28618716 PMCID: PMC5469724 DOI: 10.1186/s11671-017-2183-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/04/2017] [Accepted: 06/02/2017] [Indexed: 06/07/2023]
Abstract
In this work, we propose a method to improve electro-optical and structural parameters of light-absorbing kesterite materials. It relies on the application of weak power hydrogen plasma discharges using electromagnetic field of radio frequency range, which improves homogeneity of the samples. The method allows to reduce strain of light absorbers and is suitable for designing solar cells based on multilayered thin film structures. Structural characteristics of tetragonal kesterite Cu2ZnSn(S, Se)4 structures and their optical properties were studied by Raman, infrared, and reflectance spectroscopies. They revealed a reduction of the sample reflectivity after RF treatment and a modification of the energy band structure.
Collapse
Affiliation(s)
- Mykola O. Semenenko
- V.Ye. Lashkaryov Institute of Semiconductor Physics, National Academy of Sciences of Ukraine, Prospect Nauky 41, 03680 Kyiv, Ukraine
| | - Ivan S. Babichuk
- V.Ye. Lashkaryov Institute of Semiconductor Physics, National Academy of Sciences of Ukraine, Prospect Nauky 41, 03680 Kyiv, Ukraine
- College of Optoelectronic Engineering, Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province, Shenzhen University, 518060 Shenzhen, People’s Republic of China
| | - Oleksandr Kyriienko
- The Niels Bohr Institute, University of Copenhagen, Blegdamsvej 17, DK-2100 Copenhagen, Denmark
| | - Ivan V. Bodnar
- Belarussky Gosudarstvenniy Universitet Informatiki i Radioelektroniki – BSU-BE, P. Brovki 6, 220013 Minsk, Belarus
| | - Raquel Caballero
- Photovoltaic Materials Group, Applied Physics Department, University Autonoma of Madrid, 28049 Madrid, Spain
| | - Maximo Leon
- Photovoltaic Materials Group, Applied Physics Department, University Autonoma of Madrid, 28049 Madrid, Spain
| |
Collapse
|
23
|
Molinero L, Albanell J, Koeppen H, Martinez de Dueñas E, Halligan D, Guerrero A, Chacón López-Muñiz J, Perez R, Antolin S, Blancas I, Muñoz M, Oltra A, LÓpez de Ceballos M, Sánchez-Aragó M, Caballero R, Carrasco E, González-Angulo A, Lluch A, Mittendorff E, Rojo F. Analysis of stroma and immune-related gene expression patterns during breast cancer (BC) progression. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx391.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
24
|
Ocana Fernandez A, Ruiz Borrego M, Gil Martin M, Antolin S, Atienza M, Montaño A, Ribelles N, Guerrero A, Muñoz M, Fernández-Pérez I, Urruticoechea A, Falcon Gonzalez A, Pernas Simon S, Prato Varela J, Escudero M, Benito S, Caballero R, Carrasco E, Rojo F, Pandiella A. A phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
25
|
Rojo F, Ruiz Borrego M, Hui M, Trigo Perez J, Cazet A, Karsdal M, Urruticoechea A, Antolin S, García-Saenz J, O’Toole S, Blach A, Perez-Ramos L, Bezares S, Sánchez-Aragó M, Caballero R, Bager C, Swarbrick A, Martin Jimenez M. Tumor microenvironment biomarkers as therapeutic strategies for TNBC. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx391.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Delpon E, Tinaquero D, Alfayate S, Nieto-Marin P, Utrilla R, Matamoros M, Perez-Hernandez M, Tamargo M, Toquero J, Cosio F, Peinado R, Perez-Villacastin J, Bernal J, Tamargo J, Caballero R. P6281A DLG1 polymorphism shortens the action potential duration and the QT interval. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p6281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Caballero R, Alfayate S, Utrilla R, Nieto-Marin P, Tinaquero D, Perez-Hernandez M, Matamoros M, Herron T, Campbell K, Lopez-Sendon J, Peinado R, Jalife J, Tamargo J, Delpon E. P5836A mutation in the gene encoding the tbx5 transcription factor is associated with the Brugada Syndrome. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Fraile Sanz A, Casado Alvarez R, Caballero R, Delpon E, Perea J, Alcon B, Gil-Fournier B, Ramiro-Leon S, Pavon R, Lesmes F, Thuissard I, Lefort M, Tamargo J, Alonso J, G Cosio F. P1584A HCN4 previously undescribed variant in a large kindred with familial atrial fibrillation. Europace 2017. [DOI: 10.1093/ehjci/eux158.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Weigand A, Horn A, Caballero R, Stern A, Wilker E, Press D, Pascual-Leone A, Fox M. Prefrontal-limbic connectivity predicts antidepressant efficacy of individual rTMS sites. Brain Stimul 2017. [DOI: 10.1016/j.brs.2017.01.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
30
|
Moreno F, Martínez-Jañez N, Garau I, Guerra JA, Alarcón J, Bermejo B, Gonzalez-Cortijo L, Bueno C, Lao J, Bezares S, Rosell L, Blanch A, Caballero R, Carrasco E, Rojo F, Martín M, O'Connor M, Hernando A, Albanell J. Abstract OT3-02-07: A phase II study to compare fulvestrant (F) 500mg plus placebo versus (vs) F 500mg plus palbociclib (P) as first line treatment for postmenopausal women with hormone receptor (HR)-positive advanced breast cancer (BC) sensitive to endocrine therapy (ET). “The FLIPPER study” (GEICAM/2014-12). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot3-02-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Delaying/overcoming resistance to ET in HR-positive HER2-negative BC patients (pts) is a major need to futhrt improve safe and efficacious treatment options. F is a selective estrogen receptor (ER) downregulator currently indicated for the treatment of HR-positive metastatic BC in postmenopausal women with disease progression following anti-estrogen therapy. In FIRST trial F 500mg improved median time to progression (TTP) over anastrozole (23.4 vs 13.1 months, respectively) in untreated metastatic BC. P is a selective reversible inhibitor of cyclin-dependent kinase 4/6. FDA granted its accelerated approval based on progression-free survival (PFS) in combination with letrozole for postmenopausal women with ER-positive and HER2-negative advanced BC as initial ET (PALOMA-1). In another study, after progression to ET, P in combination with F resulted in longer PFS than F alone (PALOMA-3).
The high median TTP achieved with F alone (FIRST) coupled with the significant benefit of adding P to F (PALOMA-3) suggest that F 500mg in combination with P in the first-line setting may significantly improve long-term disease control.
Trial Design:This is an international, randomized, double-blind, multicentre phase II study comparing F 500mg in combination with P vs F 500mg plus placebo as first line therapy in postmenopausal women with HR-positive, HER2-negative metastatic BC who have received ≥5 years of adjuvant ET for early disease and remained disease free for >12 months following its completion or have “de novo” metastatic disease. HR and HER2 status will be based on central testing on the most recent tumour biopsy. Patients will be randomized 1:1. The primary objective is to compare the efficacy of both treatment arms in terms of PFS at 1 year according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator assessment. As secondary efficacy objectives,PFS, Objective Response Rate (ORR), Clinical Benefit Rate (CBR), Overall Survival (OS), and 1-year and 2-year survival probabilities, have been considered. Other secondary objectives include the comparison of safety, tolerability and health-related quality of life between the treatment arms. As exploratory objectives, the identification of promising biomarkers related with response to study therapy and primary/acquired drug resistance. Pts will be stratified by the site of disease (visceral vs non-visceral) and disease presentation at study entry (recurrent disease vs metastatic “de novo”). With a sample size of 190 pts, the analysis would have 80% power to detect a difference between both treatment arms, assuming PFS proportions of 0.545 and 0.695, respectively. This study is sponsored by GEICAM and Cancer Trials Ireland (formerly ICORG) is also participating. Recruitment started in February 2016 with 14 pts included. Analysis of the primary endpoint is planned for Q1 2018. ClinicalTrials.gov identifier:NCT02690480.
Citation Format: Moreno F, Martínez-Jañez N, Garau I, Guerra JA, Alarcón J, Bermejo B, Gonzalez-Cortijo L, Bueno C, Lao J, Bezares S, Rosell L, Blanch A, Caballero R, Carrasco E, Rojo F, Martín M, O'Connor M, Hernando A, Albanell J. A phase II study to compare fulvestrant (F) 500mg plus placebo versus (vs) F 500mg plus palbociclib (P) as first line treatment for postmenopausal women with hormone receptor (HR)-positive advanced breast cancer (BC) sensitive to endocrine therapy (ET). “The FLIPPER study” (GEICAM/2014-12) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT3-02-07.
Collapse
Affiliation(s)
- F Moreno
- Hospital Clínico Universitario San Carlos, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Son Llátzer, Palma de Mallorca, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Son Espasses, Palma de Mallorca, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Hospital Universitario Quirón Madrid, Madrid, Spain; Hospital Universitario Infanta Cristina, Madrid, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; GEICAM (Spanish Breast Cancer Group), Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón-Universidad Complutense de Madrid, Madrid, Spain; ICORG (Cancer Trials Ireland), Ireland; Hospital del Mar - IMAS, Barcelona, Spain
| | - N Martínez-Jañez
- Hospital Clínico Universitario San Carlos, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Son Llátzer, Palma de Mallorca, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Son Espasses, Palma de Mallorca, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Hospital Universitario Quirón Madrid, Madrid, Spain; Hospital Universitario Infanta Cristina, Madrid, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; GEICAM (Spanish Breast Cancer Group), Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón-Universidad Complutense de Madrid, Madrid, Spain; ICORG (Cancer Trials Ireland), Ireland; Hospital del Mar - IMAS, Barcelona, Spain
| | - I Garau
- Hospital Clínico Universitario San Carlos, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Son Llátzer, Palma de Mallorca, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Son Espasses, Palma de Mallorca, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Hospital Universitario Quirón Madrid, Madrid, Spain; Hospital Universitario Infanta Cristina, Madrid, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; GEICAM (Spanish Breast Cancer Group), Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón-Universidad Complutense de Madrid, Madrid, Spain; ICORG (Cancer Trials Ireland), Ireland; Hospital del Mar - IMAS, Barcelona, Spain
| | - JA Guerra
- Hospital Clínico Universitario San Carlos, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Son Llátzer, Palma de Mallorca, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Son Espasses, Palma de Mallorca, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Hospital Universitario Quirón Madrid, Madrid, Spain; Hospital Universitario Infanta Cristina, Madrid, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; GEICAM (Spanish Breast Cancer Group), Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón-Universidad Complutense de Madrid, Madrid, Spain; ICORG (Cancer Trials Ireland), Ireland; Hospital del Mar - IMAS, Barcelona, Spain
| | - J Alarcón
- Hospital Clínico Universitario San Carlos, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Son Llátzer, Palma de Mallorca, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Son Espasses, Palma de Mallorca, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Hospital Universitario Quirón Madrid, Madrid, Spain; Hospital Universitario Infanta Cristina, Madrid, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; GEICAM (Spanish Breast Cancer Group), Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón-Universidad Complutense de Madrid, Madrid, Spain; ICORG (Cancer Trials Ireland), Ireland; Hospital del Mar - IMAS, Barcelona, Spain
| | - B Bermejo
- Hospital Clínico Universitario San Carlos, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Son Llátzer, Palma de Mallorca, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Son Espasses, Palma de Mallorca, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Hospital Universitario Quirón Madrid, Madrid, Spain; Hospital Universitario Infanta Cristina, Madrid, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; GEICAM (Spanish Breast Cancer Group), Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón-Universidad Complutense de Madrid, Madrid, Spain; ICORG (Cancer Trials Ireland), Ireland; Hospital del Mar - IMAS, Barcelona, Spain
| | - L Gonzalez-Cortijo
- Hospital Clínico Universitario San Carlos, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Son Llátzer, Palma de Mallorca, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Son Espasses, Palma de Mallorca, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Hospital Universitario Quirón Madrid, Madrid, Spain; Hospital Universitario Infanta Cristina, Madrid, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; GEICAM (Spanish Breast Cancer Group), Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón-Universidad Complutense de Madrid, Madrid, Spain; ICORG (Cancer Trials Ireland), Ireland; Hospital del Mar - IMAS, Barcelona, Spain
| | - C Bueno
- Hospital Clínico Universitario San Carlos, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Son Llátzer, Palma de Mallorca, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Son Espasses, Palma de Mallorca, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Hospital Universitario Quirón Madrid, Madrid, Spain; Hospital Universitario Infanta Cristina, Madrid, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; GEICAM (Spanish Breast Cancer Group), Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón-Universidad Complutense de Madrid, Madrid, Spain; ICORG (Cancer Trials Ireland), Ireland; Hospital del Mar - IMAS, Barcelona, Spain
| | - J Lao
- Hospital Clínico Universitario San Carlos, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Son Llátzer, Palma de Mallorca, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Son Espasses, Palma de Mallorca, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Hospital Universitario Quirón Madrid, Madrid, Spain; Hospital Universitario Infanta Cristina, Madrid, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; GEICAM (Spanish Breast Cancer Group), Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón-Universidad Complutense de Madrid, Madrid, Spain; ICORG (Cancer Trials Ireland), Ireland; Hospital del Mar - IMAS, Barcelona, Spain
| | - S Bezares
- Hospital Clínico Universitario San Carlos, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Son Llátzer, Palma de Mallorca, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Son Espasses, Palma de Mallorca, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Hospital Universitario Quirón Madrid, Madrid, Spain; Hospital Universitario Infanta Cristina, Madrid, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; GEICAM (Spanish Breast Cancer Group), Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón-Universidad Complutense de Madrid, Madrid, Spain; ICORG (Cancer Trials Ireland), Ireland; Hospital del Mar - IMAS, Barcelona, Spain
| | - L Rosell
- Hospital Clínico Universitario San Carlos, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Son Llátzer, Palma de Mallorca, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Son Espasses, Palma de Mallorca, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Hospital Universitario Quirón Madrid, Madrid, Spain; Hospital Universitario Infanta Cristina, Madrid, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; GEICAM (Spanish Breast Cancer Group), Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón-Universidad Complutense de Madrid, Madrid, Spain; ICORG (Cancer Trials Ireland), Ireland; Hospital del Mar - IMAS, Barcelona, Spain
| | - A Blanch
- Hospital Clínico Universitario San Carlos, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Son Llátzer, Palma de Mallorca, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Son Espasses, Palma de Mallorca, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Hospital Universitario Quirón Madrid, Madrid, Spain; Hospital Universitario Infanta Cristina, Madrid, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; GEICAM (Spanish Breast Cancer Group), Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón-Universidad Complutense de Madrid, Madrid, Spain; ICORG (Cancer Trials Ireland), Ireland; Hospital del Mar - IMAS, Barcelona, Spain
| | - R Caballero
- Hospital Clínico Universitario San Carlos, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Son Llátzer, Palma de Mallorca, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Son Espasses, Palma de Mallorca, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Hospital Universitario Quirón Madrid, Madrid, Spain; Hospital Universitario Infanta Cristina, Madrid, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; GEICAM (Spanish Breast Cancer Group), Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón-Universidad Complutense de Madrid, Madrid, Spain; ICORG (Cancer Trials Ireland), Ireland; Hospital del Mar - IMAS, Barcelona, Spain
| | - E Carrasco
- Hospital Clínico Universitario San Carlos, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Son Llátzer, Palma de Mallorca, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Son Espasses, Palma de Mallorca, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Hospital Universitario Quirón Madrid, Madrid, Spain; Hospital Universitario Infanta Cristina, Madrid, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; GEICAM (Spanish Breast Cancer Group), Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón-Universidad Complutense de Madrid, Madrid, Spain; ICORG (Cancer Trials Ireland), Ireland; Hospital del Mar - IMAS, Barcelona, Spain
| | - F Rojo
- Hospital Clínico Universitario San Carlos, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Son Llátzer, Palma de Mallorca, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Son Espasses, Palma de Mallorca, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Hospital Universitario Quirón Madrid, Madrid, Spain; Hospital Universitario Infanta Cristina, Madrid, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; GEICAM (Spanish Breast Cancer Group), Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón-Universidad Complutense de Madrid, Madrid, Spain; ICORG (Cancer Trials Ireland), Ireland; Hospital del Mar - IMAS, Barcelona, Spain
| | - M Martín
- Hospital Clínico Universitario San Carlos, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Son Llátzer, Palma de Mallorca, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Son Espasses, Palma de Mallorca, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Hospital Universitario Quirón Madrid, Madrid, Spain; Hospital Universitario Infanta Cristina, Madrid, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; GEICAM (Spanish Breast Cancer Group), Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón-Universidad Complutense de Madrid, Madrid, Spain; ICORG (Cancer Trials Ireland), Ireland; Hospital del Mar - IMAS, Barcelona, Spain
| | - M O'Connor
- Hospital Clínico Universitario San Carlos, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Son Llátzer, Palma de Mallorca, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Son Espasses, Palma de Mallorca, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Hospital Universitario Quirón Madrid, Madrid, Spain; Hospital Universitario Infanta Cristina, Madrid, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; GEICAM (Spanish Breast Cancer Group), Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón-Universidad Complutense de Madrid, Madrid, Spain; ICORG (Cancer Trials Ireland), Ireland; Hospital del Mar - IMAS, Barcelona, Spain
| | - A Hernando
- Hospital Clínico Universitario San Carlos, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Son Llátzer, Palma de Mallorca, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Son Espasses, Palma de Mallorca, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Hospital Universitario Quirón Madrid, Madrid, Spain; Hospital Universitario Infanta Cristina, Madrid, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; GEICAM (Spanish Breast Cancer Group), Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón-Universidad Complutense de Madrid, Madrid, Spain; ICORG (Cancer Trials Ireland), Ireland; Hospital del Mar - IMAS, Barcelona, Spain
| | - J Albanell
- Hospital Clínico Universitario San Carlos, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Son Llátzer, Palma de Mallorca, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Son Espasses, Palma de Mallorca, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Hospital Universitario Quirón Madrid, Madrid, Spain; Hospital Universitario Infanta Cristina, Madrid, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; GEICAM (Spanish Breast Cancer Group), Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón-Universidad Complutense de Madrid, Madrid, Spain; ICORG (Cancer Trials Ireland), Ireland; Hospital del Mar - IMAS, Barcelona, Spain
| |
Collapse
|
31
|
de la Cruz-Merino L, Chiesa M, Caballero R, Rojo F, Palazón N, Carrasco FH, Sánchez-Margalet V. Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives. Int Rev Cell Mol Biol 2016; 331:1-53. [PMID: 28325210 DOI: 10.1016/bs.ircmb.2016.09.008] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Cancer immunology has gained renewed interest in the past few years due to emerging findings on mechanisms involved in tumoral immune evasion. Indisputably, immune edition is currently considered a critical hallmark of cancer. Basic research has revealed new targets which can be modulated in the clinical setting with new compounds and strategies. As recent evidence confirms, breast cancer (BC) is a complex and heterogeneous disease in which host immune responses play a substantial role. T-infiltrating lymphocytes measurement is suggested as a powerful new tool necessary to predict early BC evolution, especially in HER2-positive and triple negative subtypes. However, T-infiltrating lymphocytes, genomic platforms, and many other biomarkers in tissue and peripheral blood (e.g., regulatory T cells and myeloid-derived suppressor cells) are not the only factors being evaluated regarding their potential role as prognostic and/or predictive factors. Many ongoing clinical trials are exploring the activity of immune checkpoint modulators in BC treatment, both in the advanced and neoadjuvant setting. Although this field is expanding with exciting new discoveries and promising clinical results-and creating great expectations-there remain many uncertainties yet to be addressed satisfactorily before this long awaited therapeutic promise can come to fruition.
Collapse
Affiliation(s)
| | - M Chiesa
- GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain
| | - R Caballero
- GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain
| | - F Rojo
- Fundación Jiménez Díaz, Madrid, Spain
| | - N Palazón
- GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain
| | - F H Carrasco
- GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain
| | | |
Collapse
|
32
|
Fernandez AO, Templeton A, Casas M, Sánchez-Aragó M, Caballero R, Lescure AR, Ruiz A, Alba E, Calvo L, Ruiz M, Santaballa A, Rodríguez C, Crespo C, Ramos M, Marco JG, Lluch-Hernandez A, Alvarez I, Carrasco E, Amir E, Martin M. Prognostic role for derived neutrophil-to-lymphocyte ratio in early breast cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw364.02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Haba J, Ruiz A, Pollan M, Prat A, Rojo F, Martin M, Conejo EA, Perez-Fidalgo J, Gavilá J, Morales C, Navarro B, Hernández-Blanquisett A, Porras I, Rodriguez-Lescure A, Jiménez-Rodríguez B, Martín N, Pérez-Ramos L, Caballero R, Carrasco E, Lluch-Hernandez A. Gestational breast cancer: distinctive molecular and clinico-epidemiological features. GEICAM/2012-03 study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw364.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Chica-Parrado M, Santonja A, Lluch-Hernandez A, Albanell J, Sanchez-Muñoz A, Chacón I, Calvo L, Sanchez-Rovira P, De Haba J, Vicioso L, Martin M, Plazaola A, Prat A, Ribelles N, Sánchez-Aragó M, Jerez J, Escudero M, Caballero R, Carrasco E, Conejo EA. Luminal androgen receptor role and pathological complete response rate to neoadjuvant chemotherapy in triple negative breast cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw364.43] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Haba J, Aguilar EA, Morales S, García-Sáenz J, Guerrero A, Martínez N, Antón A, Muñoz M, Ramos M, Gil-Gil M, Margelí M, Servitja S, Bermejo B, Cruz J, Lescure AR, Casas M, Sánchez-Aragó M, Caballero R, Carrasco E, Martin M. ACE and CXCL10 as predictive biomarkers in the LEA study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.83] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Caballero R, Ibañez D, Yanguas N, Pérez MF, Aísa G. Things are not always what they seem (other causes of hepato-splenic nodules). Neth J Med 2016; 74:175. [PMID: 27185780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- R Caballero
- Department of Internal Medicine, Hospital Reina Sofía, Tudela (Navarra), Spain
| | | | | | | | | |
Collapse
|
37
|
Caballero R, Ibañez D, Yanguas N, Pérez MF, Aísa G. Answer to Photo Quiz: Things are not always what they seem (other causes of hepato-splenic nodules). Neth J Med 2016; 74:176. [PMID: 27185781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- R Caballero
- Department of Internal Medicine, Hospital Reina Sofía, Tudela (Navarra), Spain
| | | | | | | | | |
Collapse
|
38
|
Prat A, de la Haba-Rodriguez J, Guerrero Á, García-Sáenz JA, Morales S, Antón A, Muñoz M, Ramos M, Martínez-Jáñez N, Margelí M, Servitja S, Rojo F, Galván P, González S, Cruz J, Sánchez-Rovira P, Perelló A, Rodríguez-Martin C, Casas M, Carrasco E, Caballero R, Martín M. Abstract P3-07-42: Predicting outcome and benefit to first-line bevacizumab in advanced/metastatic hormone receptor (HR)+/HER2-negative breast cancer (BC) treated with endocrine therapy: A correlative science study from the LEA phase III clinical trial (GEICAM/2006-11_GBG 051). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-07-42] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The role of bevacizumab in combination with chemotherapy in metastatic BC is controversial, and no biomarker exists as of today that predicts benefit to this agent. In the LEA clinical trial, a numerical, statistically non-significant benefit from the addition of bevacizumab to endocrine therapy (ET) was observed in the first-line metastatic setting (18.4 vs. 13.8 months of Progression-Free Survival (PFS), p=0.14). Here, we explored various gene expression-based predictors of outcome and benefit to bevacizumab.
Methods and materials: LEA trial randomized 380 patients with HR+/HER2- advanced disease to bevacizumab in combination with ET (ET+B) vs. ET alone. Primary endpoint was PFS. Expression of BC selected genes was evaluated in formalin-fixed paraffin-embedded (FFPE) primary tumors using the nCounter platform from patients randomized in Spain that consent for biomarker analyses. The following variables were evaluated: 1) research-based PAM50 intrinsic subtypes (categorical variable; Luminal A, Luminal B, HER2-enriched, Basal-like and Normal-like); 2) research-based PAM50 signatures (continuous variable; scores showing the distant of the gene expression values of an individual sample compared to the centroid gene values for each PAM50 intrinsic subtype); 3) risk of recurrence (ROR) groups (low, medium and high); 4) the 13-gene hypoxia/VEGF signature (continuous); and 5) Ki67 by immunohistochemistry (continuous). Uni- and multivariable Cox models for PFS were used to test the prognostic significance of each variable. To determine whether each variable is predictive of bevacizumab benefit, we tested the interaction term of each variable by treatment arm in a Cox model.
Results: Tumor samples from 103 patients were analyzed: 55 (53%) in ET+B arm and 49 (47%) in ET arm. Subtype distribution was as follows: 57 (55.3%) Luminal A, 32 (31.1%) Luminal B, 5 (4.9%) HER2-enriched, 1 (1.0%) Basal-like, and 8 (7.8%) normal-like. In a univariate analysis, Luminal B tumors had a poorer outcome using Luminal A as reference (13.8 vs. 21.3 months, respectively; (hazard ratio, HR=1.80, 95% CI 1.10-2.95, p=0.019). Concordant with this finding, Luminal A signature was associated with a better outcome. Similarly, ROR-P high group showed a poorer outcome than ROR-P low group (8.5 vs. 19.4 months; HR=2.88, 95% CI 1.30-6.35, p=0.009). Neither VEGF-13 signature nor Ki67 were found to be associated with PFS. Similar findings were obtained after adjustment for treatment, age, previous ET, ECOG, visceral disease and number of metastatic sites. In terms of treatment benefit, the HER2-enriched signature was the only variable found predictive of bevacizumab PFS benefit in univariate (p=0.010) and multivariate (p=0.015) analyses.
Conclusions: In advanced HR+/HER2- disease, intrinsic subtype (i.e. Luminal A vs. B) independently predicts PFS following first-line ET. In addition, HR+/HER2-negative tumors with high expression of the HER2-enriched signature, a biomarker of estrogen-independence, benefit the most from bevacizumab. Further validation of these prognostic and predictive biomarkers is warranted.
Citation Format: Prat A, de la Haba-Rodriguez J, Guerrero Á, García-Sáenz JA, Morales S, Antón A, Muñoz M, Ramos M, Martínez-Jáñez N, Margelí M, Servitja S, Rojo F, Galván P, González S, Cruz J, Sánchez-Rovira P, Perelló A, Rodríguez-Martin C, Casas M, Carrasco E, Caballero R, Martín M. Predicting outcome and benefit to first-line bevacizumab in advanced/metastatic hormone receptor (HR)+/HER2-negative breast cancer (BC) treated with endocrine therapy: A correlative science study from the LEA phase III clinical trial (GEICAM/2006-11_GBG 051). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-07-42.
Collapse
Affiliation(s)
- A Prat
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - J de la Haba-Rodriguez
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - Á Guerrero
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - JA García-Sáenz
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - S Morales
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - A Antón
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - M Muñoz
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - M Ramos
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - N Martínez-Jáñez
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - M Margelí
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - S Servitja
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - F Rojo
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - P Galván
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - S González
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - J Cruz
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - P Sánchez-Rovira
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - A Perelló
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - C Rodríguez-Martin
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - M Casas
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - E Carrasco
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - R Caballero
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - M Martín
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| |
Collapse
|
39
|
Ocaña A, Ruiz Borrego M, Gil-Martín M, Antolín S, Guerrero Á, Vidal Boixader L, Martín M, Trigo Pérez JM, Rojo F, Jerez Y, Atienza M, Pernas S, Hernando A, Carrasco E, Benito S, Caballero R, Pandiella A. Abstract OT3-01-02: A phase I-II trial of dasatinib in combination with trastuzumab (T) and paclitaxel in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients: GEICAM/2010-04. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-ot3-01-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Resistance to targeted-therapies is a current problem in our clinical practice. In HER2 overexpressing tumors, resistance to trastuzumab-based therapies is widely observed. Expression of SRC has been pre-clinically linked to trastuzumab resistance and the addition of the multi-tyrosine kinase inhibitor dasatinib to trastuzumab increases its antitumor activity (Seoane S, et al. J Natl Cancer Inst. 2010). On previous studies, Dasatinib showed a good toxicity profile, with low grade 3-4 toxicity rates (E. Mayer, et al. J Clin Oncol 2009). We have designed a phase I-II trial combining dasatinib with standard trastuzumab/paclitaxel. (ClinicalTrials.gov Identifier: NCT01306942). In this abstract we report the description of the phase II part of the trial which is ongoing.
Trial Design: Eligible patients must be HER2+ (evaluated by central laboratory and assessed by immunohistochemistry and fluorescent in-situ hybridization) MBC and candidates for trastuzumab + chemotherapy as first line treatment. Taxanes and trastuzumab administered in the adjuvant setting are permitted if given >12 months before the inclusion. Patients with CNS involvement are eligible if treated and clinically stable without medication. Treatment consists of trastuzumab 2 mg/kg weekly (following a loading dose of 4 mg/kg in cycle 1), weekly paclitaxel (80 mg/m2, 3 weeks on-one week off) and dasatinib 100 mg once daily (based on the recommended phase II dose from the phase I part, Gil-Martin M, et al. European Breast Cancer Conference 2014, P-041) in a 28-days cycle. Patients are treated until radiologic or symptomatic progression or unacceptable toxicity.
The primary objective for this phase II is efficacy, measured by Objective Response Rate (ORR according to RECIST 1.1). Secondary objectives are: Safety (evaluated using NCI-CTCAE v 4.03), Clinical Benefit Rate, Time to Progression, Progression Free Survival and Response Duration. Pharmacodynamic biomarkers include pAKT, pS6, pSRC, pErk1/2 in tumor tissue samples, mononuclear cells in blood samples and in skin tissue. An additional exploratory objective is to evaluate the correlation between the early presence of lymphocytosis and efficacy. The study will be considered positive if ORR increases 25% from a 50% ORR observed in previous studies with paclitaxel + trastuzumab. We need to include 28 evaluable patients to demonstrate this hypothesis (with an alpha error of 0.05 and a statistical power of 80%), assuming a 10% drop-out rate. Twenty one patients have already been included. Recruitment is expected to finish by the end of 2015.
Citation Format: Ocaña A, Ruiz Borrego M, Gil-Martín M, Antolín S, Guerrero Á, Vidal Boixader L, Martín M, Trigo Pérez JM, Rojo F, Jerez Y, Atienza M, Pernas S, Hernando A, Carrasco E, Benito S, Caballero R, Pandiella A. A phase I-II trial of dasatinib in combination with trastuzumab (T) and paclitaxel in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients: GEICAM/2010-04. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr OT3-01-02.
Collapse
Affiliation(s)
- A Ocaña
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - M Ruiz Borrego
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - M Gil-Martín
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - S Antolín
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - Á Guerrero
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - L Vidal Boixader
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - M Martín
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - JM Trigo Pérez
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - F Rojo
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - Y Jerez
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - M Atienza
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - S Pernas
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - A Hernando
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - E Carrasco
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - S Benito
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - R Caballero
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| | - A Pandiella
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain
| |
Collapse
|
40
|
Prat A, Martínez de Dueñas E, Galván P, Garcia S, Burgués O, Paré L, Antolín S, Martinello R, Blancas I, Adamo B, Guerrero Á, Muñoz M, Nuciforo P, Vidal M, Pérez RM, Chacón JI, Caballero R, Gascón P, Carrasco E, Rojo F, Perou CM, Cortés J, Adamo V, Albanell J, Lluch A. Abstract P6-05-02: Intrinsic subtype and gene expression changes between primary and metastatic breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-05-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A better understanding of the biological changes occurring during metastatic progression of breast cancer is needed to identify new biomarkers, targets and novel treatment strategies. Here, we compared the intrinsic subtype and the expression of a gene panel across a large dataset of paired primary and metastatic tissues.
Methods: Expression profiling of 105 breast cancer-related genes was performed on 254 (127 pairs) formalin-fixed paraffin-embedded tumor tissues using the nCounter platform. Tumor samples were obtained from 3 independent sources (ConvertHER trial [BCRT 2014] and two in-house datasets). Tumors were classified into each intrinsic subtype using the research-based PAM50 classifier (Parker et al. J Clin Oncol 2009). Chi-square tests were performed to determine the differences in the distribution of variables. Paired two-class Significance of Microarrays (SAM) was performed to determine the genes differentially expressed between paired primary and metastatic tissues. In vitro stable transfection of FGFR4-GFP was performed on Luminal B MCF7 cell line. RNA was purified on control vs. transfected cell lines. 7-AAD cell viability was performed following estrogen deprivation for 6 days.
Results: Subtype distribution in primary vs. metastatic disease was 39.0% vs. 26.8% for Luminal A (p=0.012), 26.0% vs. 35.0% for Luminal B (p=0.322), 11.4% vs. 20.3% for HER2-enriched (p=0.115) and 10.6% vs. 13.0% for Basal-like tumors (p=0.843). The rate of subtype conversion was 7.7% in Basal-like, 23.1% in HER2-enriched, 30.0% in Luminal B and 54.3% in Luminal A disease. The majority of subtype conversions in Luminal A disease were to Luminal B (72.0%) and HER2-enriched (24.0%). Overall, 13.2% of primary Luminal A/B tumors progressed to a HER2-E subtype despite 70% of them being clinically HER2-negative. In a paired analysis using all samples, 10- and 12- genes were found up- and down- regulated in metastatic tissues (False Discovery Rate [FDR] <5%). The up-regulated gene list in metastatic disease was composed of FGFR4 (top gene) and proliferation genes (CDC6, CCNB1, CEP55). The down-regulated gene list in metastatic disease was enriched for luminal-related genes (ESR1, PGR, NAT1 and MAPT). A similar paired analysis within Luminal A, Luminal B, HER2-enriched and Basal-like disease revealed 22, 8, 7 and 0 differentially expressed genes (FDR<5%), respectively. Finally, MCF7 cell line transfected with FGFR4 showed a relative increase in the HER2-enriched profile compared with transfected control. In vitro, MCF7-FGFR4 cells showed estrogen independent growth compared to transfected controls.
Conclusions: Metastatic tissues are relatively more proliferative and less luminal compared to primary tumors. This is especially relevant in primary Luminal A disease. In contrast, metastatic tissues from Basal-like primary disease remain largely unchanged. In luminal disease, a significant increase in the HER2-enriched profile is observed in metastatic disease despite most tumors being clinically HER2-negative. A potential driver of the HER2-enriched profile and estrogen independence in clinically HER2-negative metastatic tissues might be FGFR4.
Citation Format: Prat A, Martínez de Dueñas E, Galván P, Garcia S, Burgués O, Paré L, Antolín S, Martinello R, Blancas I, Adamo B, Guerrero Á, Muñoz M, Nuciforo P, Vidal M, Pérez RM, Chacón JI, Caballero R, Gascón P, Carrasco E, Rojo F, Perou CM, Cortés J, Adamo V, Albanell J, Lluch A. Intrinsic subtype and gene expression changes between primary and metastatic breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-05-02.
Collapse
Affiliation(s)
- A Prat
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - E Martínez de Dueñas
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - P Galván
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - S Garcia
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - O Burgués
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - L Paré
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - S Antolín
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - R Martinello
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - I Blancas
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - B Adamo
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - Á Guerrero
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - M Muñoz
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - P Nuciforo
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - M Vidal
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - RM Pérez
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - JI Chacón
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - R Caballero
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - P Gascón
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - E Carrasco
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - F Rojo
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - CM Perou
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - J Cortés
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - V Adamo
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - J Albanell
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| | - A Lluch
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic -- IDIBAPS, Barcelona, Spain; Hospital Provincial de Castellón, Castellón, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Clínico San Cecilio de Granada, Granada, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Fundación Jiménez Díaz, Madrid, Spain; University of North Carolina, Chapel Hill, NC; University of Messina, Messina, Italy; Hospital del Mar, Barcelona, Spain
| |
Collapse
|
41
|
Abou-Ras D, Caballero R, Streeck C, Beckhoff B, In JH, Jeong S. Comprehensive Comparison of Various Techniques for the Analysis of Elemental Distributions in Thin Films: Additional Techniques. Microsc Microanal 2015; 21:1644-1648. [PMID: 26365537 DOI: 10.1017/s1431927615015093] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
In a recent publication by Abou-Ras et al., various techniques for the analysis of elemental distribution in thin films were compared, using the example of a 2-µm thick Cu(In,Ga)Se2 thin film applied as an absorber material in a solar cell. The authors of this work found that similar relative Ga distributions perpendicular to the substrate across the Cu(In,Ga)Se2 thin film were determined by 18 different techniques, applied on samples from the same identical deposition run. Their spatial and depth resolutions, their measuring speeds, their availabilities, as well as their detection limits were discussed. The present work adds two further techniques to this comparison: laser-induced breakdown spectroscopy and grazing-incidence X-ray fluorescence analysis.
Collapse
Affiliation(s)
- Daniel Abou-Ras
- 1Helmholtz-Zentrum Berlin für Materialien und Energie GmbH,Hahn-Meitner-Platz 1,14109 Berlin,Germany
| | - Raquel Caballero
- 1Helmholtz-Zentrum Berlin für Materialien und Energie GmbH,Hahn-Meitner-Platz 1,14109 Berlin,Germany
| | - Cornelia Streeck
- 2Physikalisch-Technische Bundesanstalt,Abbestr. 2-12,10587 Berlin,Germany
| | - Burkhard Beckhoff
- 2Physikalisch-Technische Bundesanstalt,Abbestr. 2-12,10587 Berlin,Germany
| | - Jung-Hwan In
- 3School of Mechatronics,Gwangju Institute of Science and Technology,1 Oryong-dong,Buk-gu,Gwangju 500-712,Republic of Korea
| | - Sungho Jeong
- 3School of Mechatronics,Gwangju Institute of Science and Technology,1 Oryong-dong,Buk-gu,Gwangju 500-712,Republic of Korea
| |
Collapse
|
42
|
Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, Ruiz-Borrego M, Munarriz B, López JA, Adamo B, Cheang MCU, Li Y, Hu Z, Gulley ML, Vidal MJ, Pitcher BN, Liu MC, Citron ML, Ellis MJ, Mardis E, Vickery T, Hudis CA, Winer EP, Carey LA, Caballero R, Carrasco E, Martín M, Perou CM, Alba E. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br J Cancer 2014; 111:1532-41. [PMID: 25101563 PMCID: PMC4200088 DOI: 10.1038/bjc.2014.444] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2014] [Revised: 06/26/2014] [Accepted: 07/13/2014] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND In this study, we evaluated the ability of gene expression profiles to predict chemotherapy response and survival in triple-negative breast cancer (TNBC). METHODS Gene expression and clinical-pathological data were evaluated in five independent cohorts, including three randomised clinical trials for a total of 1055 patients with TNBC, basal-like disease (BLBC) or both. Previously defined intrinsic molecular subtype and a proliferation signature were determined and tested. Each signature was tested using multivariable logistic regression models (for pCR (pathological complete response)) and Cox models (for survival). Within TNBC, interactions between each signature and the basal-like subtype (vs other subtypes) for predicting either pCR or survival were investigated. RESULTS Within TNBC, all intrinsic subtypes were identified but BLBC predominated (55-81%). Significant associations between genomic signatures and response and survival after chemotherapy were only identified within BLBC and not within TNBC as a whole. In particular, high expression of a previously identified proliferation signature, or low expression of the luminal A signature, was found independently associated with pCR and improved survival following chemotherapy across different cohorts. Significant interaction tests were only obtained between each signature and the BLBC subtype for prediction of chemotherapy response or survival. CONCLUSIONS The proliferation signature predicts response and improved survival after chemotherapy, but only within BLBC. This highlights the clinical implications of TNBC heterogeneity, and suggests that future clinical trials focused on this phenotypic subtype should consider stratifying patients as having BLBC or not.
Collapse
Affiliation(s)
- A Prat
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Pg Vall d'Hebron, 119-129, 08035 Barcelona, Spain
- Department of Medicine, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain
| | - A Lluch
- Department of Medical Oncology and Department of Pathology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain
| | - J Albanell
- Department of Medical Oncology, Hospital del Mar, IMIM, 08003 Barcelona, Spain
- Department of Medical Oncology, Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain
| | - W T Barry
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
| | - C Fan
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA
| | - J I Chacón
- Department of Medical Oncology, Hospital Virgen de la Salud, 45004 Toledo, Spain
| | - J S Parker
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA
- Department of Genetics, University of North Carolina, Chapel Hill, NC 27519, USA
| | - L Calvo
- Department of Medical Oncology, Complexo Hospitalario Universitario de A Coruña, 15002 A Coruña, Spain
| | - A Plazaola
- Department of Medical Oncology, Onkologikoa, 20014 San Sebastián, Spain
| | - A Arcusa
- Department of Medical Oncology, Consorci Sanitari de Terrassa, 08225 Barcelona, Spain
| | - M A Seguí-Palmer
- Department of Medical Oncology, Corporació Sanitària Parc Taulí, 08208 Sabadell, Spain
| | - O Burgues
- Department of Medical Oncology and Department of Pathology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain
| | - N Ribelles
- Department of Medical Oncology and Department of Pathology, Hospital Universitario Virgen de la Victoria, 29010 Malaga, Spain
| | - A Rodriguez-Lescure
- Department of Medical Oncology, Hospital General de Elche, 03203 Alicante, Spain
| | - A Guerrero
- Department of Medical Oncology, Instituto Valenciano de Oncología (IVO), 46009 Valencia, Spain
| | - M Ruiz-Borrego
- Department of Medical Oncology, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain
| | - B Munarriz
- Department of Medical Oncology, Hospital Universitario La Fe, 46026 Valencia, Spain
| | - J A López
- Department of Medical Oncology, Hospital San Camilo, 28006 Madrid, Spain
| | - B Adamo
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Pg Vall d'Hebron, 119-129, 08035 Barcelona, Spain
| | - M C U Cheang
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA
| | - Y Li
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA
| | - Z Hu
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA
| | - M L Gulley
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA
| | - M J Vidal
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Pg Vall d'Hebron, 119-129, 08035 Barcelona, Spain
| | - B N Pitcher
- Alliance Statistical and Data Center, Duke University, Durham, NC 27708, USA
| | - M C Liu
- Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
| | - M L Citron
- ProHEALTH Care Associates, LLP, Lake Success, NY 11803, USA
| | - M J Ellis
- Department of Oncology, Washington University, St. Louis, MO 63130, USA
| | - E Mardis
- Department of Oncology, Washington University, St. Louis, MO 63130, USA
| | - T Vickery
- Department of Oncology, Washington University, St. Louis, MO 63130, USA
| | - C A Hudis
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - E P Winer
- Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
| | - L A Carey
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA
| | - R Caballero
- GEICAM (Spanish Breast Cancer Research Group), 28700 Madrid, Spain
| | - E Carrasco
- GEICAM (Spanish Breast Cancer Research Group), 28700 Madrid, Spain
| | - M Martín
- GEICAM (Spanish Breast Cancer Research Group), 28700 Madrid, Spain
- Department of Medical Oncology, Instituto de Investigación Sanitaria Hospital Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense, 28007 Madrid, Spain
| | - C M Perou
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA
- Department of Genetics, University of North Carolina, Chapel Hill, NC 27519, USA
- Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27519, USA
| | - E Alba
- Department of Medical Oncology and Department of Pathology, Hospital Universitario Virgen de la Victoria, 29010 Malaga, Spain
| |
Collapse
|
43
|
Daimi H, N Dominguez J, Hernandez-Torres F, Chinchilla A, Aranega A, Caruz A, Vazquez E, Hove-Madsen L, Caballero R, Franco D. 279Pitx2 regulates multiple AF associated GWAS genes. Cardiovasc Res 2014. [DOI: 10.1093/cvr/cvu085.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Caballero R, Matamoros M, Perez-Hernandez M, Dolz-Gaiton P, Barana A, Amoros I, Nunez M, Gonzalez De La Fuente M, Tamargo J, Delpon E. Human cardiac Kir2.1, but not Kir2.3, channel expression is regulated by Nav1.5. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht310.p5019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Prat A, Cheang M, Martín M, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard P, Nielsen T, Perou C. 10O_PR Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically-Defined Luminal A Breast Cancer. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(19)65682-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
46
|
Perez-Pomares JM, Ruiz-Villalba A, Ziogas A, Segovia JC, Ehrbar M, Munoz-Chapuli R, De La Rosa A, Dominguez JN, Hove-Madsen L, Sankova B, Sedmera D, Franco D, Aranega Jimenez A, Babaeva G, Chizh N, Galchenko S, Sandomirsky B, Schwarzl M, Seiler S, Steendijk P, Huber S, Maechler H, Truschnig-Wilders M, Pieske B, Post H, Simrick S, Kreutzer R, Rao C, Terracciano CM, Kirchhof P, Fabritz L, Brand T, Theveniau-Ruissy M, Parisot P, Francou A, Saint-Michel E, Mesbah K, Kelly RG, Wu HT, Sie SS, Chen CY, Kuan TC, Lin CS, Ismailoglu Z, Guven M, Yakici A, Ata Y, Ozcan S, Yildirim E, Ongen Z, Miroshnikova V, Demina E, Rodygina T, Kurjanov P, Denisenko A, Schwarzman A, Rubanenko A, Shchukin Y, Germanov A, Goldbergova M, Parenica J, Lipkova J, Pavek N, Kala P, Poloczek M, Vasku A, Parenicova I, Spinar J, Gambacciani C, Chiavacci E, Evangelista M, Vesentini N, Kusmic C, Pitto L, Chernova A, Nikulina SUY, Arvanitis DA, Mourouzis I, Pantos C, Kranias EG, Cokkinos DV, Sanoudou D, Vladimirskaya TE, Shved IA, Kryvorot SG, Schirmer IM, Appukuttan A, Pott L, Jaquet K, Ladilov Y, Archer CR, Bootman MD, Roderick HL, Fusco A, Sorriento D, Santulli G, Trimarco B, Iaccarino G, Hagenmueller M, Riffel J, Gatzoulis MA, Stoupel EG, Garcia R, Merino D, Montalvo C, Hurle MA, Nistal JF, Villar AV, Perez-Moreno A, Gilabert R, Bernhold E, Ros E, Amat-Roldan I, Katus HA, Hardt SE, Maqsood A, Zi M, Prehar S, Neyses L, Ray S, Oceandy D, Khatami N, Wadowski P, Wagh V, Hescheler J, Sachinidis A, Mohl W, Chaudhry B, Burns D, Henderson DJ, Bax NAM, Van Marion MH, Shah B, Goumans MJ, Bouten CVC, Van Der Schaft DWJ, Bax NAM, Van Oorschot AAM, Maas S, Braun J, Van Tuyn J, De Vries AAF, Gittenberger-De Groot AC, Goumans MJ, Bageghni S, Drinkhill MJ, Batten TFC, Ainscough JFX, Onate B, Vilahur G, Ferrer-Lorente R, Ybarra J, Diez-Caballero A, Ballesta-Lopez C, Moscatiello F, Herrero J, Badimon L, Martin-Rendon E, Clifford DM, Fisher SA, Brusnkill SJ, Doree C, Mathur A, Clarke M, Watt SM, Hernandez-Vera R, Badimon L, Kavanagh D, Yemm AI, Frampton J, Kalia N, Terajima Y, Shimizu T, Tsuruyama S, Ishii H, Sekine H, Hagiwara N, Okano T, Vrijsen KR, Chamuleau SAJ, Sluijter JPG, Doevendans PFM, Madonna R, Delli Pizzi S, Di Donato L, Mariotti A, Di Carlo L, D'ugo E, Teberino MA, Merla A, T A, De Caterina R, Kolker L, Ali NN, Maclellan K, Moore M, Wheeler J, Harding SE, Fleck RA, Rowlinson JM, Kraenkel N, Ascione R, Madeddu P, O'sullivan JF, Leblond AL, Kelly G, Kumar AHS, Metharom P, Buneker CK, Alizadeh-Vikali N, Hynes BG, O'connor R, Caplice NM, Noseda M, De Smith AJ, Leja T, Rao PH, Al-Beidh F, Abreu Pavia MS, Blakemore AI, Schneider MD, Stathopoulou K, Cuello F, Ehler E, Haworth RS, Avkiran M, Morawietz H, Eickholt C, Langbein H, Brux M, Goettsch C, Goettsch W, Arsov A, Brunssen C, Mazilu L, Parepa IR, Suceveanu AI, Suceveanu AP, De Man FS, Guignabert C, Tu L, Handoko ML, Schalij I, Fadel E, Postmus PE, Vonk-Noordegraaf A, Humbert M, Eddahibi S, Sorriento D, Santulli G, Del Giudice C, Anastasio A, Trimarco B, Iaccarino G, Fazal L, Azibani F, Bihry N, Merval R, Polidano E, Samuel JL, Delcayre C, Zhang Y, Mi YM, Ren LL, Cheng YP, Guo R, Liu Y, Jiang YN, Mourouzis I, Pantos C, Kokkinos AD, Cokkinos DV, Tretjakovs P, Jurka A, Bormane I, Mikelsone I, Reihmane D, Elksne K, Krievina G, Verbovenko J, Bahs G, Lopez-Andres N, Rousseau A, Calvier L, Akhtar R, Labat C, Cruickshank K, Diez J, Zannad F, Lacolley P, Rossignol P, Hamesch K, Subramanian P, Li X, Thiemann A, Heyll K, Dembowsky K, Chevalier E, Weber C, Schober A, Yang L, Kim G, Gardner B, Earley J, Hofmann-Bowman M, Cheng CF, Lian WS, Lin H, Jinjolia NJ, Abuladze GA, Tvalchrelidze SHT, Khamnagadaev I, Shkolnikova M, Kokov L, Miklashevich I, Drozdov I, Ilyich I, Bingen BO, Askar SFA, Ypey DL, Van Der Laarse A, Schalij MJ, Pijnappels DA, Roney CH, Ng FS, Chowdhury RA, Chang ETY, Patel PM, Lyon AR, Siggers JH, Peters NS, Obergrussberger A, Stoelzle S, Bruggemann A, Haarmann C, George M, Fertig N, Moreira D, Souza A, Valente P, Kornej J, Reihardt C, Kosiuk J, Arya A, Hindricks G, Adams V, Husser D, Bollmann A, Camelliti P, Dudhia J, Dias P, Cartledge J, Connolly DJ, Terracciano CM, Nobles M, Sebastian S, Tinker A, Opel A, Tinker A, Daimi H, Haj Khelil A, Be Chibani J, Barana A, Amoros I, Gonzalez De La Fuente M, Caballero R, Aranega A, Franco D, Kelly A, Bernus O, Kemi OJ, Myles RC, Ghouri IA, Burton FL, Smith GL, Del Lungo M, Sartiani L, Spinelli V, Baruscotti M, Difrancesco D, Mugelli A, Cerbai E, Thomas AM, Aziz Q, Khambra T, Tinker A, Addlestone JMA, Cartwright EJ, Wilkinson R, Song W, Marston S, Jacquet A, Mougenot NM, Lipskaia AJ, Paalberends ER, Stam K, Van Dijk SJ, Van Slegtenhorst M, Dos Remedios C, Ten Cate FJ, Michels M, Niessen HWM, Stienen GJM, Van Der Velden J, Read MI, Andreianova AA, Harrison JC, Goulton CS, Kerr DS, Sammut IA, Schwarzl M, Seiler S, Wallner M, Huber S, Steendijk P, Maechler H, Truschnig-Wilders M, Von Lewinski D, Pieske B, Post H, Kindsvater D, Saes M, Morano I, Muegge A, Jaquet K, Buyandelger B, Kostin S, Gunkel S, Vouffo J, Ng K, Chen J, Eilers M, Isaacson R, Milting H, Knoell R, Cattin ME, Crocini C, Schlossarek S, Maron S, Hansen A, Eschenhagen T, Carrier L, Bonne G, Coppini R, Ferrantini C, Olivotto I, Del Lungo M, Belardinelli L, Poggesi C, Mugelli A, Cerbai E, Leung MC, Messer AE, Copeland O, Marston SB, Mills AM, Collins T, O'gara P, Thum T, Regalla K, Lyon AR, Macleod KT, Harding SE, Rao C, Prodromakis T, Chaudhry U, Darzi A, Yacoub MH, Athanasiou T, Terracciano CM, Bogdanova A, Makhro A, Hoydal M, Stolen TO, Johnssen AB, Alves M, Catalucci D, Condorelli G, Koch LG, Britton SL, Smith GL, Wisloff U, Bito V, Claus P, Vermeulen K, Huysmans C, Ventura-Clapier R, Sipido KR, Seliuk MN, Burlaka AP, Sidorik EP, Khaitovych NV, Kozachok MM, Potaskalova VS, Driesen RB, Galan DT, Vermeulen K, Claus P, Sipido KR, De Paulis D, Arnoux T, Schaller S, Pruss RM, Poitz DM, Augstein A, Braun-Dullaeus RC, Schmeisser A, Strasser RH, Micova P, Balkova P, Hlavackova M, Zurmanova J, Kasparova D, Kolar F, Neckar J, Novak F, Novakova O, Pollard S, Babba M, Hussain A, James R, Maddock H, Alshehri AS, Baxter GF, Dietel B, Altendorf R, Daniel WG, Kollmar R, Garlichs CD, Sirohi R, Roberts N, Lawrence D, Sheikh A, Kolvekar S, Yap J, Arend M, Walkinshaw G, Hausenloy DJ, Yellon DM, Posa A, Szabo R, Szalai Z, Szablics P, Berko MA, Orban K, Murlasits ZS, Balogh L, Varga C, Ku HC, Su MJ, Chreih RM, Ginghina C, Deleanu D, Ferreira ALBJ, Belal A, Ali MA, Fan X, Holt A, Campbell R, Schulz R, Bonanad C, Bodi V, Sanchis J, Morales JM, Marrachelli V, Nunez J, Forteza MJ, Chaustre F, Gomez C, Chorro FJ, Csont T, Fekete V, Murlasits Z, Aypar E, Bencsik P, Sarkozy M, Varga ZV, Ferdinandy P, Duerr GD, Zoerlein M, Dewald D, Mesenholl B, Schneider P, Ghanem A, Rittling S, Welz A, Dewald O, Duerr GD, Dewald D, Becker E, Peigney C, Ghanem A, Welz A, Dewald O, Bouleti C, Galaup A, Monnot C, Ghaleh B, Germain S, Timmermans A, Ginion A, De Meester C, Sakamoto K, Vanoverschelde JL, Horman S, Beauloye C, Bertrand L, Maroz-Vadalazhskaya N, Drozd E, Kukharenko L, Russkich I, Krachak D, Seljun Y, Ostrovski Y, Martin AC, Le Bonniec B, Lecompte T, Dizier B, Emmerich J, Fischer AM, Samama CM, Godier A, Mogensen S, Furchtbauer EM, Aalkjaer C, Choong WL, Jovanovic A, Khan F, Daniel JM, Dutzmann JM, Widmer-Teske R, Guenduez D, Sedding D, Castro MM, Cena JJC, Cho WJC, Goobie GG, Walsh MPW, Schulz RS, Daniel JM, Dutzmann J, Widmer-Teske R, Preissner KT, Sedding D, Aziz Q, Khambra T, Sones W, Thomas AM, Kotlikoff M, Tinker A, Serizawa K, Yogo K, Aizawa K, Hirata M, Tashiro Y, Ishizuka N, Varela A, Katsiboulas M, Tousoulis D, Papaioannou TG, Vaina S, Davos CH, Piperi C, Stefanadis C, Basdra EK, Papavassiliou AG, Hermenegildo C, Lazaro-Franco M, Sobrino A, Bueno-Beti C, Martinez-Gil N, Walther T, Peiro C, Sanchez-Ferrer CF, Novella S, Ciccarelli M, Franco A, Sorriento D, Del Giudice C, Dorn GW, Trimarco B, Iaccarino G, Cseplo P, Torok O, Springo ZS, Vamos Z, Kosa D, Hamar J, Koller A, Bubb KJ, Ahluwalia A, Stepien EL, Gruca A, Grzybowska J, Goralska J, Dembinska-Kiec A, Stepien EL, Stolinski J, Grzybowska J, Goralska J, Partyka L, Gruca A, Dembinska-Kiec A, Zhang H, Sweeney D, Thomas GN, Fish PV, Taggart DP, Watt SM, Martin-Rendon E, Cioffi S, Bilio M, Martucciello S, Illingworth E, Caporali A, Shantikumar S, Marchetti M, Martelli F, Emanueli C, Marchetti M, Meloni M, Caporali A, Al Haj Zen A, Sala-Newby G, Emanueli C, Del Turco S, Saponaro C, Dario B, Sartini S, Menciassi A, Dario P, La Motta C, Basta G, Santiemma V, Bertone C, Rossi F, Michelon E, Bianco MJ, Castelli A, Shin DI, Seung KB, Seo SM, Park HJ, Kim PJ, Baek SH, Shin DI, Seung KB, Seo SM, Park HJ, Choi YS, Her SH, Kim DB, Kim PJ, Lee JM, Park CS, Rocchiccioli S, Cecchettini A, Pelosi G, Kusmic C, Citti L, Parodi O, Trivella MG, Michel-Monigadon D, Burger F, Dunoyer-Geindre S, Pelli G, Cravatt B, Steffens S, Didangelos A, Mayr U, Yin X, Stegemann C, Shalhoub J, Davies AH, Monaco C, Mayr M, Lypovetska S, Grytsenko S, Njerve IU, Pettersen AA, Opstad TB, Bratseth V, Arnesen H, Seljeflot I, Dumitriu IE, Baruah P, Antunes RF, Kaski JC, Forteza MJ, Bodi V, Trapero I, Benet I, Alguero C, Chaustre FJ, Gomez C, Sanchis J, Chorro FJ, Mangold A, Puthenkalam S, Distelmaier K, Adlbrecht C, Preissner KT, Lang IM, Koizumi T, Inoue I, Komiyama N, Nishimura S, Korneeva ON, Drapkina OM, Fornai L, Angelini A, Kiss A, Giskes F, Eijkel G, Fedrigo M, Valente ML, Thiene G, Heeren RMA, Vilahur G, Padro T, Casani L, Suades R, Badimon L, Bertoni B, Carminati R, Carlini V, Pettinari L, Martinelli C, Gagliano N, Noppe G, Buchlin P, Marquet N, Baeyens N, Morel N, Vanoverschelde JL, Bertrand L, Beauloye C, Horman S, Baysa A, Sagave J, Dahl CP, Gullestad L, Carpi A, Di Lisa F, Giorgio M, Vaage J, Valen G, Vafiadaki E, Papalouka V, Arvanitis DA, Terzis G, Spengos K, Kranias EG, Manta P, Sanoudou D, Gales C, Genet G, Dague E, Cazorla O, Payre B, Mias C, Ouille A, Lacampagne A, Pathak A, Senard JM, Abonnenc M, Da Costa Martins P, Srivastava S, Didangelos A, Yin X, Gautel M, De Windt L, Mayr M, Comelli L, Rocchiccioli S, Lande C, Ucciferri N, Trivella MG, Citti L, Cecchettini A, Ikonen L, Vuorenpaa H, Kujala K, Sarkanen JR, Heinonen T, Ylikomi T, Aalto-Setala K, Capros H, Sprincean N, Usurelu N, Egorov V, Stratu N, Matchkov V, Bouzinova E, Moeller-Nielsen N, Wiborg O, Aalkjaer C, Gutierrez PS, Aparecida-Silva R, Borges LF, Moreira LFP, Dias RR, Kalil J, Stolf NAG, Zhou W, Suntharalingam K, Brand N, Vilar Compte R, Ying L, Bicknell K, Dannoura A, Dash P, Brooks G, Tsimafeyeu I, Tishova Y, Wynn N, Oyeyipo IP, Olatunji LA, Maegdefessel L, Azuma J, Toh R, Raaz U, Merk DR, Deng A, Spin JM, Tsao PS, Lande C, Cecchettini A, Tedeschi L, Taranta M, Naldi I, Citti L, Trivella MG, Grimaldi S, Cinti C, Bousquenaud M, Maskali F, Poussier S, Marie PY, Boutley H, Karcher G, Wagner DR, Devaux Y, Torre I, Psilodimitrakopoulos S, Iruretagoiena I, Gonzalez-Tendero A, Artigas D, Loza-Alvarez P, Gratacos E, Amat-Roldan I, Murray L, Carberry DM, Dunton P, Miles MJ, Suleiman MS, Kanesalingam K, Taylor R, Mc Collum CN, Parniczky A, Solymar M, Porpaczy A, Miseta A, Lenkey ZS, Szabados S, Cziraki A, Garai J, Koller A, Myloslavska I, Menazza SM, Canton MC, Di Lisa FDL, Schulz RS, Oliveira SHV, Morais CAS, Miranda MR, Oliveira TT, Lamego MRA, Lima LM, Goncharova NS, Naymushin AV, Kazimli AV, Moiseeva OM, Lima LM, Carvalho MG, Sabino AP, Mota APL, Sousa MO, Niessner A, Richter B, Hohensinner PJ, Rychli K, Zorn G, Berger R, Moertl D, Pacher R, Wojta J, Huelsmann M, Kukharchik G, Nesterova N, Pavlova A, Gaykovaya L, Krapivka N, Konstantinova I, Sichinava L, Prapa S, Mccarthy KP, Kilner PJ, Xu XY, Johnson MR, Ho SY. Poster session 2. Cardiovasc Res 2012. [DOI: 10.1093/cvr/cvr334] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
47
|
Abou-Ras D, Schaffer B, Schaffer M, Schmidt SS, Caballero R, Unold T. Direct insight into grain boundary reconstruction in polycrystalline Cu(In,Ga)SE2 with atomic resolution. Phys Rev Lett 2012; 108:075502. [PMID: 22401224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Received: 10/27/2011] [Indexed: 05/31/2023]
Abstract
This work presents results from high-resolution scanning transmission electron microscopy and electron energy-loss spectroscopy on twin boundaries (TBs) and nontwin grain boundaries (GBs) in Cu(In,Ga)Se(2) thin films. It is shown that the atomic reconstruction is different for different symmetries of the grain boundaries. We are able to confirm the model proposed by Persson and Zunger [Phys. Rev. Lett. 91, 266401 (2003)] for Se-Se-terminated Σ3 {112} TBs, showing Cu depletion and In enrichment in the two atomic planes closest to the TB. On the contrary, Cu depletion without In enrichment is detected for a cation-Se-terminated TB. At nontwin GBs, always a strong anticorrelation of Cu and In signals is detected suggesting that the formation of In(Cu) or Cu(In) antisites within a very confined region of smaller than 1 nm is an essential element in the reconstruction of these GBs.
Collapse
Affiliation(s)
- Daniel Abou-Ras
- Helmholtz-Zentrum Berlin für Materialien und Energie, Berlin, Germany.
| | | | | | | | | | | |
Collapse
|
48
|
Blancas FJ, Lozano-Oyola M, González M, Guerrero FM, Caballero R. How to use sustainability indicators for tourism planning: the case of rural tourism in Andalusia (Spain). Sci Total Environ 2011; 412-413:28-45. [PMID: 22033358 DOI: 10.1016/j.scitotenv.2011.09.066] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/13/2011] [Revised: 09/23/2011] [Accepted: 09/23/2011] [Indexed: 05/31/2023]
Abstract
This paper proposes an indicators system to analyse the sustainability of tourist activity at rural destinations in countries with a consolidated tourism sector. The proposed system aims at providing tourist managers and policy-makers with information to better understand the transition to sustainability at specific destinations and to encourage them to carry out corresponding policy and management responses. To illustrate how indicators can be quantified, we create a practical guideline on how to use the statistical information available. Likewise, we suggest a method for obtaining sustainability indexes by aggregation that reduces the subjectivity associated with the composite indicator. This procedure is based on the combination of principal component analysis and distance to a reference point. Together with the definition of sustainable tourism indicators, we explain how to use these systems and sustainability indexes to fulfil three practical uses in tourism sector planning: the comparison and characterisation of destinations, the definition of benchmarking practices, and the quantification of sustainable tourism objectives. Each practical use is illustrated using the case of rural zones in a consolidated destination such as Andalusia.
Collapse
Affiliation(s)
- F J Blancas
- Department of Economics, Quantitative Methods and Economic History, Pablo de Olavide University, Seville, Spain.
| | | | | | | | | |
Collapse
|
49
|
Abou-Ras D, Caballero R, Fischer CH, Kaufmann CA, Lauermann I, Mainz R, Mönig H, Schöpke A, Stephan C, Streeck C, Schorr S, Eicke A, Döbeli M, Gade B, Hinrichs J, Nunney T, Dijkstra H, Hoffmann V, Klemm D, Efimova V, Bergmaier A, Dollinger G, Wirth T, Unger W, Rockett AA, Perez-Rodriguez A, Alvarez-Garcia J, Izquierdo-Roca V, Schmid T, Choi PP, Müller M, Bertram F, Christen J, Khatri H, Collins RW, Marsillac S, Kötschau I. Comprehensive comparison of various techniques for the analysis of elemental distributions in thin films. Microsc Microanal 2011; 17:728-751. [PMID: 21906418 DOI: 10.1017/s1431927611000523] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
The present work shows results on elemental distribution analyses in Cu(In,Ga)Se2 thin films for solar cells performed by use of wavelength-dispersive and energy-dispersive X-ray spectrometry (EDX) in a scanning electron microscope, EDX in a transmission electron microscope, X-ray photoelectron, angle-dependent soft X-ray emission, secondary ion-mass (SIMS), time-of-flight SIMS, sputtered neutral mass, glow-discharge optical emission and glow-discharge mass, Auger electron, and Rutherford backscattering spectrometry, by use of scanning Auger electron microscopy, Raman depth profiling, and Raman mapping, as well as by use of elastic recoil detection analysis, grazing-incidence X-ray and electron backscatter diffraction, and grazing-incidence X-ray fluorescence analysis. The Cu(In,Ga)Se2 thin films used for the present comparison were produced during the same identical deposition run and exhibit thicknesses of about 2 μm. The analysis techniques were compared with respect to their spatial and depth resolutions, measuring speeds, availabilities, and detection limits.
Collapse
Affiliation(s)
- D Abou-Ras
- Helmholtz-Zentrum Berlin für Materialien und Energie, Hahn-Meitner-Platz 1, 14109 Berlin, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
Atrial fibrillation (AF), the most common cardiac arrhythmia, is associated with substantial morbidity and mortality. Dronedarone is an amiodarone-like benzofuran which lacks the iodine moiety and presents a methane sulfonyl group that decreases its lipophilicity, thus shortening the half-life and decreasing tissue accumulation. Like amiodarone, dronedarone blocks multiple cardiac ion channels and β-adrenoceptors, presenting electrophysiological characteristics of all four Vaughan Williams classes of antiarrhythmic drugs. In clinical trials, dronedarone has been found effective for both rhythm and rate control. Dronedarone was more effective than placebo in maintaining sinus rhythm in patients with paroxysmal and/or persistent AF and was also effective for ventricular rate control during AF recurrences, providing incremental rate control on top of standard drugs in permanent AF. Furthermore, in the ATHENA trial, dronedarone reduced the incidence of hospitalization due to cardiovascular events or death in patients with nonpermanent AF. Even when dronedarone was less effective than amiodarone in decreasing AF recurrence, it had a better safety profile, being devoid of thyroid, pulmonary and neurological toxicity. This review analyzes the electrophysiological and pharmacological properties, as well as the efficacy and safety of dronedarone in patients with atrial fibrillation.
Collapse
Affiliation(s)
- J Tamargo
- Department of Pharmacology, Universidad Complutense, Madrid, Spain.
| | | | | | | |
Collapse
|